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1. Introduction
1.1.  Cardiovascular disease and 
dyslipidemia: prevalence and global 
economic impact 
Cardiovascular diseases (CVDs) are the lead-
ing cause of mortality worldwide, reaching 31% 
of deaths in 2012 [1]. In particular, atheroscle-
rosis and ischemic heart disease (IHD) are the 
main causes of premature death in Europe and 
are responsible for 42% of deaths in women and 
38% in men under 75 years old [2]. The global 
economic impact of CVD is estimated to have 
been US $906 billion in 2015 and is expected to 
rise by 22% by 2030 [3]. Cardiovascular diseas-
es also represent the major cause of disability 
in developed countries. It has been estimated 
that their growing burden could lead to a global 
increase in loss of disability-adjusted life years 
(DALYs), from a loss of 85 million DALYs in 1990 
to a loss of ~150 million DALYs in 2020, becom-
ing a major non-psychological cause of lost pro-
ductivity [4].
Several risk factors contribute to the etiology 
and development of CVD; they are divided into 
those modifiable through lifestyle changes or by 
taking a  pharmacologic treatment (e.g. for hy-
pertension, smoking, diabetes mellitus, hyper-
cholesterolemia) and those that are not modi-
fiable (age, male gender, and family history) [5]. 
Elevated total cholesterol (TC) and low-density 
lipoprotein cholesterol (LDL-C) blood concen-
trations are the major modifiable risk factors 
for coronary heart disease (CHD), whereas high 
concentrations of plasma high-density lipopro-
tein cholesterol (HDL-C) in certain conditions are 
considered protective [6]. Moreover, LDL-C re-
mains a fundamental CV risk factor (and a main 
target of therapy) even when statins are largely 
used in the general population [7].
An examination of the data of 18 053 partici-
pants aged ≥ 20 years who participated in the Na-
tional Health and Nutrition Examination Surveys 
(NHANES) from 1999 to 2006 showed that the un-
adjusted prevalence of hypercholesterolemia ranged 
from 53.2% to 56.1% in United States adults [8]. Dif-
ferences related to gender and race or ethnicity were 
observed; in particular, a  lower rate of control was 
found among women than men and lower rates of 
having a cholesterol check and being told about hy-
percholesterolemia were reported by African Ameri-
cans and Mexican Americans than whites [8].
A recent report from the American Heart As-
sociation confirmed that in the US only 75.7% of 
children and 46.6% of adults present targeted TC 
levels (TC < 170 mg/dl for children and < 200 mg/
dl for adults, in untreated individuals) [9]. The pat-
tern is similar in other Western countries [10, 11].
1.2.  The importance of treating 
dyslipidemia to reduce  
cardiovascular risk
Many available clinical trials and meta-analyses 
have shown a  relationship between a decrease 
in the levels of LDL-C and a reduction in relative 
risk of CVD [12]. In particular, a meta-analysis of 
the Cholesterol Treatment Trialists’ (CTT) Collabo-
ration, based on data from 14 randomized con-
trolled trials (RCTs), which involved 90 056 individ-
uals, demonstrated a greater reduction in coronary 
and vascular events, which was related to a great-
er decrease in absolute levels of LDL-C [10]. Fur-
thermore, in a report from the CTT Collaboration 
on more than 170 000 subjects, it was stated that 
with the cholesterol-lowering drug therapy, each 
further reduction of LDL-C by 1 mmol/l (~40 mg/dl) 
decreased by about one-fifth the risk of revascu-
larization, coronary artery disease and ischemic 
stroke, highlighting that a  reduction of LDL-C of 
3.2 mmol/l (125 mg/dl) could lead to a decrease 
in risk of about 40–50%, in the absence of an 
increased risk of cancer or non-CV-related death 
[13]. One mmol/l is a reduction that is achievable 
through lifestyle improvements associated with 
lipid-lowering nutraceuticals. Moreover, it has 
been estimated that every 1% reduction in LDL-C 
level corresponds to a reduction of the relative risk 
for CV events greater than about 1% [14, 15].
1.3.  Lipid targets
In all adults a fasting or non-fasting lipoprotein 
profile should be obtained at least every 5 years 
[16]. Levels of LDL-C < 100 mg/dl (~2.5 mmol/l) 
are associated with a  low risk for CHD and are 
considered optimal in the absence of CVD or oth-
er risk factors [17]. Consequently, current guide-
lines recommend achieving of LDL-C levels of 
< 115 mg/dl (~3.0 mmol/l) in patients at low and 
moderate risk for CHD. The LDL-C treatment target 
is < 100 mg/dl (~2.6 mmol/l) for patients at high 
risk and < 70 mg/dl (~1.8 mmol/l) for patients at 
very high risk [18]. 
High-risk subjects include those patients 
with prior atherosclerotic cardiovascular disease 
(ASCVD) events, including prior coronary events, 
transient ischemic attack, ischemic stroke, ath-
erosclerotic peripheral artery disease (PAD) (e.g. 
ankle/brachial index < 0.90) and other athero-
sclerotic diseases (e.g. renal atherosclerosis, ath-
erosclerotic aortic aneurysm and carotid plaque 
≥ 50% stenosed). Other patient populations con-
sidered at high risk include patients with diabetes 
mellitus (DM), chronic kidney disease (CKD; stage 
≥ 3B), and those with very high levels of individual 
risk factors, such as familial hypercholesterolemia 
(FH) [16].
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Elevated triglycerides (TGs) are also an in-
dependent risk factor for CVD, and their levels 
should be optimized in order to reduce residual 
CVD risk [19].
1.4. Lifestyle improvement
Currently, according to the severity of dyslipid-
emia and the level of CV risk, treatment is based 
on lifestyle changes that include dietary habits 
and physical activity, or pharmacological thera-
py [20]. In fact, it is important to emphasize that 
non-pharmacological management should always 
accompany the lipid-lowering therapy [21]. Life-
style treatment for hypercholesterolemia includes 
a diet low in saturated fat (< 7% of total energy), 
moderate or higher intensity physical activity (≥ 
150 min/week) and weight loss (5–10% of body 
weight) for those who are overweight or obese. 
Exposure to active or passive tobacco smoking 
must be avoided as well [22, 23].
The American Heart Association (AHA) recom-
mends a diet with a high content of fruits, vegeta-
bles, whole grains, low-fat dairy products, poultry, 
fish and nuts [24]. It also recommends limiting con-
sumption of red meat and sugary foods and bev-
erages. Many diets fit that pattern, including the 
“Dietary Approaches to Stop Hypertension” (DASH) 
and the “Mediterranean Diet” [25]. LDL-C (and non-
HDL-C) reductions with lifestyle improvements are 
most often in the range of 5% to 15%, an amount 
that, if maintained over a long period, may result in 
meaningful CVD risk reduction [5, 26, 27]. 
For patients with hypertriglyceridemia, life-
style interventions are key to reducing TGs; in-
cluding weight a loss if overweight or obese (ini-
tially targeting loss of 5–10% of body weight), 
physical activity (≥ 150 min/week of moderate 
or higher intensity activity), and restriction of 
alcohol, simple sugars, and refined carbohydrate 
intake [28].
If sufficient progress is not made towards 
achieving atherogenic cholesterol goals, consid-
eration may be given to the use of lipid-lower-
ing nutraceuticals, alone or in combination with 
pharmacological therapy, which is indicated for 
patients with borderline lipid values (out-of-tar-
get) or intolerant to drugs [29]. It is however im-
portant to strongly emphasize that nutraceuticals 
cannot replace indicated lipid-lowering therapy in 
patients at CVD risk. 
1.5.  Indication of lipid-lowering 
nutraceuticals in clinical practice
In recent years, nutraceuticals and functional 
foods have shown their role as possible supporting 
therapies for lowering plasma TC, LDL-C and TG, es-
pecially for hypercholesterolemic subjects, whose 
blood cholesterol level is moderately elevated (for 
instance, TC = 200–240 mg/dl or 5.2–6.2 mmol/l, 
LDL-C = 130–160 mg/dl or 3.4–4.1 mmol/l, 
TG = 150–200 mg/dl or 1.7–2.3 mmol/l in sub-
jects in primary prevention for CVD) but not high 
enough to require pharmacological treatment [30, 
31]. Based on current knowledge, nutraceuticals 
could exert significant lipid-lowering activity, and 
their intake has many advantages. First of all, the 
lipid-lowering effect of most nutraceuticals occurs 
through multiple mechanisms: the possibility of 
acting simultaneously on multiple stages of lip-
id-induced vascular damage makes them poten-
tial candidates for improving the lipid-lowering 
effects when used in combination with diet, drugs 
or other nutraceuticals [32]. Moreover, they can 
have a large number of positive pleiotropic effects, 
including improvement of endothelial dysfunction 
and arterial stiffness, as well as anti-inflammatory 
and anti-oxidative properties [33]. Furthermore, 
a  relatively large amount of epidemiological and 
clinical data supports the tolerability and safety 
of many nutraceuticals with demonstrated lip-
id-lowering action, including in patients intolerant 
to statins [34]. According to the European Athero-
sclerosis Society (EAS) consensus document, in 
the last 10 years a number of observational stud-
ies have reported unfavorable side effects related 
to statins, in particular musculoskeletal disorders 
(statin-associated muscle symptoms (SAMS)), 
gastrointestinal disorders and fatigue [35]. This is 
particularly relevant since it is estimated that the 
range of people intolerant to conventional statin 
treatment is between 45 000 and 290 000 individ-
uals/year [36] (complete statin intolerance is esti-
mated at less than 5%) and that statin intolerance 
represents one of the main reasons for statin dis-
continuation and non-adherence and consequent-
ly failure of lipid-lowering treatment [37–39]. 
Another group of patients who might benefit 
from such nutraceuticals consists of very old pa-
tients (especially those aged over 75) or patients 
with sarcopenia [40]. A  further category of pa-
tients who could benefit from nutraceuticals re-
fers to those already treated with statins and/or 
ezetimibe, and who have not reached the targeted 
LDL-C level although not being too far from it. The 
development of new powerful (and very expen-
sive) lipid-lowering drugs will be able to fill the gap 
(and in consequence reduce the residual CV risk), 
but their use seems to be cost-effective only for 
a  limited number of patients [41]. Therefore, nu-
traceuticals might cost-effectively fill these gaps. 
The recent 2016 European guidelines for dyslipid-
emia management consider the possibility to use 
some lipid-lowering nutraceuticals, not consider-
ing fully a number of prospective and observation-
al studies as well as a  positive meta-analysis of 
randomized clinical trials (RCTs) supporting the 
A.F.G. Cicero, A. Colletti, G. Bajraktari, O. Descamps, D.M. Djuric, M. Ezhov, Z. Fras, N. Katsiki, M. Langlois, G. Latkovskis, D.B. Panagiotakos,  
G. Paragh, D.P. Mikhailidis, O. Mitchenko, B. Paulweber, D. Pella, C. Pitsavos, Ž. Reiner, K.K. Ray, M. Rizzo, A. Sahebkar, M.C. Serban, L.S. Sperling,  
P.P. Toth, D. Vinereanu, M. Vrablík, N.D. Wong, M. Banach
970 Arch Med Sci 5, August / 2017
possible use of a  relatively large number of nat-
ural compounds [18]. Therefore the present posi-
tion paper provides an up-to-date summary of the 
findings on the lipid-lowering effects of the most 
important nutraceuticals and functional foods.
1.6.  Clinical evidence on individual  
lipid-lowering nutraceuticals
Nutraceuticals with lipid-lowering effects can 
be divided into 3 categories according to their 
mechanisms of action: natural inhibitors of intes-
tinal cholesterol absorption, inhibitors of hepatic 
cholesterol synthesis, and enhancers of the ex-
cretion of LDL-C (Figures 1–3). Nevertheless, there 
are many functional food/nutritional supplements 
with multiple or unclear mechanisms of action. 
Nutraceuticals described in the literature are nu-
merous and show different levels of effectiveness 
and evidence of their lipid-lowering effect: the 
objective of this consensus is to clarify which are 
the major nutraceuticals with the greatest evi-
dence and clinical efficacy. For each nutraceutical, 
we will briefly describe the main mechanism of 
action, active principles, effective dosages, clinical 
evidence of effects on lipid profile, extra-lipid-low-
ering properties (e.g. endothelial function and ar-
terial stiffness), and safety profile (if such data are 
available).
The level of evidence and the strength of recom-
mendation of particular lipid-lowering treatment 
options have been weighed and graded according 
to predefined scales, as outlined in Tables I and II. 
The experts of the writing and reviewing panels 
completed Declaration of interest forms where real 
or potential sources of conflicts of interest might 
be perceived (at the end of the paper). 
Following the final approval of the contents of 
the position paper, the final version of the docu-
ment is scheduled for parallel publication in Ar-
chives of Medical Science (full-scope journal), and 
Nutrition Reviews (specialized journal) in order 
to maximally increase the number of readers of 
these important recommendations. Physicians 
and medical professionals of other specialties 
treating patients with lipid disorders are encour-
aged to consider the position paper in the process 
of evaluating the clinical status of their patients, 
and determining and implementing medical strat-
egies for the prevention, diagnosis and treatment 
of dyslipidemias. However, the position paper 
does not override in any way the individual re-
sponsibility of physicians to make appropriate and 
accurate decisions taking into account the condi-
tion of a given patient, in consultation with that 
patient, and, where necessary, with the patient’s 
guardian or carer. It is also the responsibility of 
health professionals to verify the rules and regu-
Figure 1. Nutraceuticals acting as inhibitors of liver cholesterol synthesis
HMG-CoA – 3-hydroxy-3-methylglutaryl-coenzyme A, LDL-R – low-density lipoprotein receptor, PCSK9 – proprotein convertase 
subtilisin/kexin type 9, SREBP1 – sterol regulatory element-binding protein 1, VLDL – very-low-density lipoprotein.
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lations applicable to drugs and devices at the time 
of their prescription/use.
2. Inhibitors of intestinal cholesterol 
absorption
2.1.  Plant sterols and stanols
Mechanism of action: Plant sterols, present in 
almost all plant sources (in particular in vegetable 
oils, nuts, seeds, legumes and fat spreads), are 
structurally similar to cholesterol, differing in the 
side chain at C24 that presents a methyl or ethyl 
group (campesterol and B-sitosterol, respective-
ly) or an extra double bond in C22 (stigmaster-
ol) [42]. Plant sources also contain plant stanols, 
such as β-sitostanol, campestanol and stigmasta-
nol, that are saturated derivatives of sterols [43]. 
Plant sterols + stanols (PS) average daily intake 
in the common diet is low: between 150 and 
450 mg/day; however, some populations, such 
Figure 2. Nutraceuticals acting as inhibitors of intestinal cholesterol absorption and enhancers of cholesterol ex-
cretion
ABCA1 – ATP-binding cassette transporter, NPC1L1 – Niemann-Pick C1-Like 1.
Figure 3. Nutraceuticals acting on fatty acids
AMPK – AMP-activated protein kinase.
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Soluble fibers
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Curcumin
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Triglycerides
Triglycerides
Fatty acids
Acyl-CoA
Fatty acids
Acyl-CoA
↑ β-oxidation  
and ↓ synthesis
↑ β-oxidation  
and ↓ synthesis
(AMPK activation)
↑ β-oxidation
(mitochondrial  
transporter of fatty acids)
(AMPK activation)
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Policosanols
ω-3
L-carnitine
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as the Japanese or vegetarians, consume at least 
twice as much [43].
Efficacy: PS reduce LDL-C by decreasing in-
testinal absorption of exogenous cholesterol, 
competing with it in the formation of solubilized 
micelles [44, 45]. The micelles interact with the 
brush border membrane and are substrate of 
Niemann-Pick C1-Like 1 (NPC1L1) transporter 
that facilitates the transport of sterols from the 
intestinal lumen. However, the ATP-binding cas-
sette protein family (ABCG5 and ABCG8) shuttles 
and blows out again unesterified cholesterol and 
the majority of sterols and stanols in the intesti-
nal lumen [44, 45]. As a result, PS have extremely 
low bioavailability (0.5–2% rapidly excreted by 
the liver vs. 55–60% of exogenous cholesterol); 
in general, plant sterols have higher bioavailabil-
ity than stanols, probably due to a different ar-
rangement in the intestinal micelles [44, 45]. This 
determines an increase in the intestinal lumen 
of the precipitate and excreted cholesterol via 
feces. PS also intensify the expression of ABCA1 
transporter and inhibit the acyl-CoA:cholesterol 
O-acyltransferase (ACAT) enzyme, reducing the 
amount of cholesterol absorbed from 30% to 
50%. It is important to emphasize that for better 
therapeutic efficacy, an excellent vehicle for the 
PS are spreadable fats that improve their solubil-
ity, promoting dispersion and incorporation into 
micelles [44, 45].
The lipid-lowering effects of PS have been 
highlighted in several meta-analyses of RCTs. The 
meta-analysis of Ras et al. included 41 clinical tri-
als with 2084 individuals [44]. The mean dose of 
phytosterols provided was 1.6 g/day (0.3 to 3.2 g/ 
day) administered through different sources (yo-
ghurt, milk, dressing, mayonnaise, and bread), 
and the median duration of studies was 28 days 
(21–315 days). The meta-analysis showed not only 
the significant reduction of LDL-C of 0.33 mmol/l 
(12.8 mg/dl) (–8.5%), but also an average increase 
in levels of sitosterol 2.24 μmol/l (+31%) and 
campesterol 5.00 μmol/l (+37%) compared to con-
trols [44]. The increase of plasma levels of sitos-
terol and campesterol showed a dose-dependent 
trend: in fact, in the subgroup analysis a  “high 
dose” of PS (2.0 to 3.2 g/day) showed the highest 
levels of sitosterol and campesterol (on average 
3.56 and 7.64 μmol/l, respectively). However, total 
PS level remained below 1% of total sterols and 
stanols circulating in the blood [44]. PS could also 
have some impact on TG but only in patients with 
high TG levels at baseline [46]. Moreover, PS sup-
plementation has a  mild but significant improv-
ing effect on high-sensitivity C-reactive protein 
(hs-CRP) [47].
The lipid-lowering effect of PS is dose depen-
dent and proportional up to the attainment of 
a  plateau (reached at approximately 3 g/day of 
PS achieving an average effect on LDL-C of –12%) 
due to saturation of the uptake of cholesterol and 
transport process. At doses up to 3 g/day there 
were no differences in efficacy on cholesterolemia, 
between stanols and sterols [48]. Another meta- 
analysis of RCTs showed that two of the best fat 
carriers for PS are rapeseed or canola because of 
their high content of monounsaturated fatty ac-
ids and ω-3 that enhances the functionality of PS 
[45]. The effect of PS on endothelial function has 
Table I. Classes of recommendation
Class of recommendation Definition Suggested wording 
Class I Evidence and/or general agreement that a given 
treatment or procedure is beneficial, useful, 
effective
Is recommended/Is indicated
Class II Conflicting evidence and/or a divergence  
of opinion about the usefulness/ 
efficacy of the given treatment or procedure
Class IIa Weight of evidence/ opinion is in favor  
of usefulness/efficacy
Should be considered
Class IIb Usefulness/efficacy is less well established  
by evidence/opinion
May be considered
Class III Evidence or general agreement that the given 
treatment or procedure is not useful/effective and 
in some cases may be harmful
Is not recommended (no 
efficacy on lipid profile)
Table II. Level of evidence
Level of evidence Definition
Level A Data derived from multiple 
randomized clinical trials or their 
meta-analysis
Level B Data derived from single 
randomized clinical trial or large 
non-randomized studies
Level C Consensus or opinion of 
experts and/or small studies, 
retrospectives studies, registries
Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
Arch Med Sci 5, August / 2017 973
been recently investigated in two large RCTs that 
furnished conflicting results [49, 50].
Safety: In conclusion, PS produce a  mean re-
duction of LDL-C by 8–12% in subjects with hy-
percholesterolemia. PS have also shown a  high 
safety profile in the middle-term; however, data 
for treatment longer than 2 years are still not 
available [44, 50]. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIa A 400–
3000 mg
–8% to 
–12%
↓ hs-CRP Not 
demon-
strated
2.2. Soluble fibers
Dietary fibers is a  term commonly used for 
a variety of substances of vegetable origin resis-
tant to enzymatic digestion in the gastrointesti-
nal tract. Generally, they are divided according to 
their solubility into soluble and insoluble fibers 
[51]. For the last several years, some studies have 
focused on the lipid-lowering properties of soluble 
fibers, including pectin, guar gum, mucilage, oats 
and psyllium, showing a reduction in TC and LDL-C 
[51, 52]. The lipid-lowering mechanisms of action 
of soluble fibers are different, including prolonged 
gastric emptying time, an increase of satiety, the 
inhibition of hepatic cholesterol synthesis and an 
increase of fecal excretion of cholesterol and bile 
salts [52]. The reduction of cholesterol obtained by 
soluble fibers described in the literature is variable 
and dependent on the type of fiber, doses, sub-
jects treated, study size and different diets: the 
effective range of the reduction of TC varies from 
0 to 18% for oat-based fibers, 3–17% for psyllium, 
5–16% for pectin, and 4–17% for guar gum [51].
2.2.1. β-glucan 
Mechanism of action: β-glucan is a soluble fiber 
derived from the walls of different plant cells, bac-
terial, algae, fungi and yeasts. β-glucan has high 
viscosity, which confers lipid-lowering action [32].
Efficacy: A meta-analysis of 17 RCTs with 916 
patients showed that β-glucan consumption in 
a  hypercholesterolemic population significantly 
reduced LDL-C (–0.21 mmol/l (8.1 mg/dl) (95% CI: 
0.27; –0.14) p < 0.00001). However, there were 
no significant differences in HDL-C and TG. No 
adverse effects were reported among the eligi-
ble trials [53]. In 2010 the European Food Safety 
Authority (EFSA) confirmed that oat β-glucan is 
able to reduce plasmatic cholesterol levels; how-
ever, at least 3 g/day of β-glucan is necessary [54]. 
According to the American and European guide-
lines for the management of dyslipidemia, the 
consumption of 5–15 g/day (European guidelines) 
or 10–25 g/day (US guidelines) of soluble fibers 
derived from oat rich in β-glucan can essentially 
reduce the levels of cholesterol in the blood [55, 
56]. Finally, the study of Tabesh et al. showed that 
the consumption of β-glucan for 4 weeks in 60 pa-
tients with hypercholesterolemia increases the se-
rum levels of nitric oxide (NO) (p = 0.017) but has 
no effect on flow-mediated dilatation (FMD) [57].
Safety: Due to the lack of enough data it seems 
to be important to evaluate the efficacy and safe-
ty of administration of β-glucan in the long-term 
follow-up as well as to clarify whether there is 
a dose-response relationship and whether it can 
decrease the CV risk.
2.2.2. Psyllium 
Mechanism of action: Psyllium is a natural source 
of concentrated fibers derived from the husks of 
blonde psyllium seed. The mechanisms of action 
of psyllium are similar to those of other fibers dis-
cussed, including increased excretion of bile acids 
(stimulating 7α-hydroxylase), reduced absorption 
of intestinal cholesterol and a reduction of hepatic 
cholesterol synthesis (via the short-chain fatty acid 
byproducts of fiber fermentation) [58].
Efficacy: A meta-analysis of 21 studies, which 
enrolled a total of 1030 and 687 subjects receiv-
ing psyllium or placebo, respectively, concluded 
that compared with placebo, consumption of 
psyllium lowered serum LDL-C by 0.278 mmol/l 
(10.8 mg/dl) (95% CI: 0.213; 0.312 mmol/l). With 
random-effect meta-regression, a  significant 
dose-response relationship was found between 
doses (3–20.4 g/day) and total cholesterol or LDL-C 
changes. Following an average intake of psyllium 
of 10 g/day, an average reduction of LDL-C of 7% 
was observed [59]. Moreover, psyllium showed 
good efficacy also in children and adolescents, 
with the percentage of LDL-C reduction similar to 
the one in adults [60]. The reduction of cholesterol 
was more pronounced in American subjects with 
hypercholesterolemia, who consumed a  high-fat 
diet (LDL-C –8/20%) [61]. Psyllium supplementa-
tion might also have a positive effect on glucose 
metabolism related parameters [62]. However, 
psyllium has shown no significant effects on vas-
cular function [63].
Safety: All available clinical trials and meta-anal-
yses confirm the good safety profile of psyllium (at 
doses up to 20 g/day) that is documented by the 
Food and Drug Administration (FDA), the Select 
Committee on Generally Recognized Safe Sub-
stances and the Expert Panel from the Life Scienc-
es Research Office. However, in some cases minor 
gastrointestinal side effects were reported (espe-
cially with micronized fibers) that might slightly 
reduce the adherence to this nutraceutical [64].
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2.2.3. Glucomannan 
Mechanism of action: Glucomannan is a  par-
ticular soluble fiber, widely used in the Orient for 
over a  thousand years, derived from Amorpho-
phallus konjac, commonly referred as konjac root, 
available as a nutraceutical in different forms such 
as capsules, tablets and sachets. Structurally glu-
comannan is a polysaccharide constituted by glu-
cose and mannose (ratio 1 : 1.6) bound through 
β-1,4-glycosidic bonds [32]. Unlike other fibers, 
glucomannan does not act by binding bile acids, 
but it seems to reduce the absorption of cholester-
ol in the jejunum and the absorption of bile acids 
in the ileum, yielding improvements in apolipopro-
tein B (ApoB) and plasma LDL-C levels. It also in-
creases the activity of 7α-hydroxylase, an enzyme 
that converts cholesterol into bile acids [65].
Efficacy: A  recent meta-analysis including 14 
RCTs with 531 patients concluded that the use 
of glucomannan (at doses ranging between 1.24 
and 15.1 g/day) significantly reduces LDL-C and 
TG respectively by –0.41 mmol/l (15.9 mg/dl) and 
–0.13 mmol/l (11.5 mg/dl) (p < 0.05 for both) 
compared to placebo. The reduction of serum tri-
glycerides is a peculiarity of glucomannan, prob-
ably due to its high viscosity and its ability to in-
teract with the hepatic cholesterol and lipoprotein 
metabolism, but not of other soluble fibers, which 
have only a very modest action on triglyceride lev-
els [66]. Data on weight reduction are controver-
sial; in general it can be said that glucomannan is 
able to promote the maintenance of weight and 
in some cases (with at least 5.2 weeks of treat-
ment) it can cause a  small reduction of weight 
(according to some meta-analyses significant, 
according to others not), although only less than 
1 kg [67]. Treatment with glucomannan has also 
given positive results in children with primary 
hyperlipidemia. Guardamagna et al. conducted 
a study with 36 dyslipidemic children (6–15 years 
old) treated with glucomannan twice daily for 
8 weeks. The results showed a significant reduc-
tion in LDL-C (–7.3%, p = 0.008) and non-HDL-C 
(–7.2%, p = 0.002) compared to placebo. These 
effects had a more pronounced trend in females 
than in males [68]. The same correlation was 
also found in the study of Martino et al., where 
40 children were treated with 2–3 g/day of glu-
comannan and benefited by a reduction of LDL-C 
of 30% in females and 9% in males (p = 0.046). 
This gender-dependent effect was also observed 
with other soluble fibers, and it would seem to be 
caused by the interaction between sex hormones 
and lipid metabolism; nevertheless, further cor-
roboration is necessary [69]. The abovemen-
tioned results have been confirmed in a further 
study by the same authors on a larger sample of 
120 hypercholesterolemic children [70].
Safety: The intake of glucomannan may interfere 
with the absorption of certain drugs, in particular 
lipophilic drugs/nutraceuticals: for example, gluco-
mannan could reduce the absorption of vitamin E, 
calcium and other minerals, whereas it does not 
hinder the absorption of water-soluble vitamins. 
Therefore it is recommended to take the medica-
tion 1 h before or at least four hours after taking 
glucomannan [32]. In general, the consumption of 
glucomannan does not cause serious side effects; 
most of them concern gastrointestinal such as di-
arrhea, flatulence and abdominal discomfort. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIa A 5–15 g –5% to 
–15%
↓ TG, 
glyce-
mia, 
HOMA 
index, 
body 
weight
↓ CVD 
risk (ep-
idemio-
logical 
data on 
fiber-rich 
foods)
2.3. Chitosan
Mechanism of action: Chitosan is a  non-fiber 
lipid-lowering agent isolated from shellfish and 
sea crustaceans that inhibits cholesterol absorp-
tion in the bowel. 
Efficacy: A meta-analysis of 6 RCTs including 416 
patients with hypercholesterolemia concluded that it 
has a significant effect on TC (–0.3 mmol/l (11.6 mg/
dl), p = 0.002), but not on LDL-C, HDL-C or TG [71]. 
Since other trials have yielded conflicting results 
with a significant reduction of all lipid parameters 
[72], further studies are necessary to have clear data 
on efficacy both in the short and long term of con-
sumption. However, chitosan supplementation is as-
sociated with mild weight loss [73] and an improve-
ment in insulin-resistance related parameters [74].
Safety: Transient side effects such as abdomi-
nal pain, diarrhea, vomiting, and constipation oc-
cur in rare cases at doses ranging between 1 and 
6 g/day (indicative daily doses) [75].
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIb A 1–6 g –5% ↓ Body 
weight, 
glucose, 
HOMA 
index
Not 
demon-
strated
2.4. Probiotics
Mechanism of action: Probiotics are defined as 
vital microorganisms which confer health benefits 
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to the host when taken in adequate amounts. The 
consumption of probiotics is considered safe and 
free of serious side effects [76]. In recent years, 
some clinical studies have supported the hypoth-
esis of a possible clinical use of certain strains of 
microorganisms as cholesterol-lowering agents. 
Nevertheless, it is still very difficult to draw firm 
conclusions due to the great heterogeneity of the 
studies in duration, type of probiotic strains used, 
dosage, clinical characteristics of the participants 
and dosage form/vehicle.
The mechanisms of action whereby probiotics 
reduce cholesterolemia are still unclear. Among the 
proposed mechanisms, it is possible that probiotics 
interact with the intestinal cholesterol, binding or 
incorporating it into the cell membrane [77]. Lacto-
bacillus acidophilus and L. bulgaricus contain some 
enzymes (cholesterol dehydrogenase/isomerase) 
able to catalyze the transformation of cholesterol 
into cholest-4-en-3-one, an intermediate cofactor 
in the conversion of cholesterol to coprosterol or 
coprostanol, which are directly excreted in the fe-
ces [78]. Other probiotics reduce the enterohepatic 
circulation of bile salts through activity of bile salt 
hydrolase (BSH) enzymes; there is a  mechanism 
based on the ability of some lactobacilli and bifido-
bacteria to deconjugate bile acids enzymatically, in-
creasing their excretion rates and attracting greater 
mobilization of systemic cholesterol to the liver for 
de novo synthesis of bile salts [79]. Finally, some 
probiotics may alter bowel pH, the formation of mi-
celles, the transport pathways of cholesterol and/
or lipoprotein (such as NPC1L1 gene expression) 
and cholesteryl esters [80]. These mechanisms are 
hypothetical, so further well-designed studies are 
required to elucidate which of these have a greater 
influence on cholesterol reduction.
Efficacy: A  recent meta-analysis included 30 
RCTs to investigate the effect of probiotics on TC, 
HDL-C and TG and 27 RCTs on LDL-C. The most 
studied probiotic strains were L. acidophilus, 
L. acidophilus + Bifidobacterium lactis and L. plan-
tarum. The mean duration of the studies was 
7 weeks involving normo- (TC < 200 mg/dl) or hy-
percholesterolemic subjects. The pooled mean net 
change in LDL-C was –0.19 mmol/l (7.35 mg/dl) 
(p < 0.01) compared to controls. TG and HDL-C did 
not change significantly compared to the control 
groups. In a subgroup analysis, the maximum re-
duction in LDL-C was obtained in studies that in-
cluded hypercholesterolemic subjects, with higher 
levels of cholesterol at baseline [81].
Based on available data it seems that the best 
results were obtained with Lactobacillus strains. 
One possible explanation might be the adaptation 
of Lactobacillus species (in particular L. acidophi-
lus and L. plantarum) that can survive in acid and 
bile environment and easily colonize the gastro-
intestinal tract [82]. A stronger cholesterol-lower-
ing effect of Lactobacillus was confirmed in the 
meta-analysis of RCTs by Shimizu et al., where 
the most promising results were obtained after 
a treatment period of more than 4 weeks, but they 
could not prove any significant improvements in 
either HDL-C or TG [83]. More studies are needed 
to strictly define the types of subjects who would 
benefit most, the probiotic strains, the dosage 
forms or the administration vehicles of the strains 
(researching any interference or pleiotropic action 
due to the vehicle), the duration of the treatment, 
the dosages and the cholesterol-lowering mech-
anisms. To date, the clinical findings are still not 
sufficient to recommend probiotics as a nonphar-
macologic alternative to improve the lipid profile.
Safety: Probiotics are considered to be gener-
ally very safe, and side effects are rare. The report 
released by the Agency for Healthcare Research 
and Quality (2011) concluded that, although the 
existing probiotic clinical trials reveal no evidence 
of increased risk, there are not enough data to an-
swer questions on the safety of probiotics in inter-
vention studies with confidence [84]. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIb B Strain- 
depen-
dent 
–5% 
(strain- 
depen-
dent)
None 
(at least 
none 
with 
a lipid- 
lowering 
effect)
Not 
demon-
strated
3. Inhibitors of liver cholesterol synthesis
3.1. Red yeast rice extract
Mechanism of action: Red yeast rice (RYR) is 
a  nutraceutical obtained by the fermentation of 
a particular yeast (in general Monascus purpureus, 
M. pilosus, M. floridanus or M. ruber) in rice (Ory-
za sativa) that gives the typical red coloration to 
the rice for the presence of pigments produced 
by the secondary fermentative metabolism. Red 
yeast rice contains sugars (25–73%, in particular 
starch), proteins (14–31%), water (2–7%), fatty ac-
ids (1–5%), pigments (such as rubropunctamine, 
monascorubramine, rubropunctatin, monascoru-
brin, monascin, ankaflavin), sterols, isoflavones 
and polyketides [85]. The yeast during the fermen-
tation process enriches the rice of a  complex of 
substances with important lipid-lowering activ-
ities including polyketides such as monacolins. 
Usually the food supplements derived from red 
yeast rice contain a  concentration of monaco-
lins of up to 1.9% [86]. Based on the conditions 
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of fermentation and the yeast strain used, today 
several types of monacolins have been identified 
(compactin, monacolins M, L, J, X) including the 
subtype monacolin K (MonK), structurally identical 
to lovastatin. The main cholesterol-lowering puta-
tive mechanism of action of red yeast rice is due by 
a reversible inhibitory action on 3-hydroxy-3-meth-
yl-glutaryl-CoA (HMG-CoA) reductase (the key en-
zyme in endogenous cholesterol synthesis).
Despite having the same structure, MonK and 
lovastatin pharmacokinetic profiles and bioavail-
ability can be different: in fact, if on one hand lo-
vastatin is administered in conventional pharma-
ceutical form as a  single active ingredient (31% 
of bioavailability in humans), MonK is only one of 
the components of the red yeast rice that can in-
teract to change the typical pharmacokinetic pro-
file of lovastatin. Another important aspect that 
emphasizes the possible pharmacokinetics and 
clinical efficacy differences regards the chemical 
structure of MonK: the ratio of lactone to acid 
strongly varies, the acid being the active one and 
much better absorbed. The acid form can range 
from 5% to 100% of the total MonK (difficult to 
estimate), greatly influencing the bioavailability of 
the molecule. The lactone ring opening can occur 
following metabolism in alkaline conditions or en-
zymatically by the small intestine and liver cyto-
chrome P450 (CYP) 3A family [87, 88].
Efficacy: The lipid-lowering efficacy of RYR has 
been confirmed by some meta-analyses of RCTs; 
the most recent one included 20 trials evaluating 
the efficacy and safety profile of this nutraceuti-
cal. The results showed that (after 2–24 months) 
RYR reduced LDL-C on average by 1.02 mmol/l 
(–1.20; –0.83) (39.4 mg/dl) compared to placebo, 
which was not different from moderate-intensity 
statins (pravastatin 40 mg, simvastatin 10 mg, 
lovastatin 20 mg) (0.003 mmol/l; –0.36; 0.41) 
(0.12 mg/dl). A  small increase of HDL-C (0.007 
mmol/l; 0.03; 0.11) (0.3 mg/dl) and decrease of 
TG (–0.26 mmol/l; –0.35; –0.17) (23 mg/dl) com-
pared to placebo was observed. The doses of RYR 
used were different and varied from 1200 mg to 
4800 mg/day containing from 4.8 mg to 24 mg 
of MonK. Concerning the safety profile, the inci-
dence of cases of liver abnormalities and kidney 
injury was between 0 and 5% in both groups (RYR 
and control). In addition, the incidence of develop-
ing muscular symptoms was lower in RYR groups 
(0 to 23.8%) compared to control groups (0–36%). 
There were no cases of rhabdomyolysis or myop-
athy with CK levels increased more than 10 times 
the upper limit [89]. In fact it has been clearly 
shown that the safety profile of RYR is similar to 
that of low-dose statins [90]. These data consol-
idate the results obtained in a previous Chinese 
meta-analysis including 93 trials with a  total of 
9625 participants included [91]. 
The reason why the reduction of serum choles-
terol is comparable between “RYR” and “statin” 
groups (at doses many times higher than the cor-
responding MonK) is still unclear. It is possible that 
“non-statin components” of RYR (such as polyun-
saturated fatty acids) exert pleiotropic actions on 
reducing cholesterol, thus reaching the values as 
the groups treated with single-component statins 
[85]. Furthermore, the tolerance of RYR is usually 
greater than statin treatment. The reason is again 
not clear, but it could be explained by the fact that 
the daily dose of MonK in dietary supplements is 
usually much lower than that of statins.
RYR also improves endothelial function in hu-
mans. In a clinical trial involving 50 patients with 
CHD, treated with 1200 mg/day of RYR or placebo 
for a period of 6 weeks and following a meal with 
high fat intake (50 g), the levels of hs-CRP and FMD 
(at 0 and 4 h) and the lipid parameters were mon-
itored. The results showed that the group treated 
with RYR at the end of the 6-week follow-up ob-
tained a reduction of hs-CRP and the area under 
the curve (AUC) of triglyceride (TG-AUC) (p < 0.001 
for each), in addition to an improvement of post-
prandial and pre-prandial FMD (p < 0.001). There 
were no significant changes in serum lipids and 
FMD in the placebo group [92]. 
RYR use is a  rare example of a  nutraceutical 
studied to evaluate its effects on CV outcomes. 
RYR supplementation has shown relevant efficacy 
in reducing CVD risk in adult and elderly patients 
in secondary prevention [92]. In a  large trial in-
volving 66 hospitals in China, 1445 patients (aged 
between 65 and 75 years) with a history of myo-
cardial infarction (MI) were randomized to two 
groups (placebo vs. RYR) and followed for a mean 
of 4 years. RYR supplementation showed a  re-
duction in the risk of CHD (31.0%, p = 0.04), all-
cause mortality (31.9%, p = 0.01), stroke (44.1%, 
p = 0.04), the need for coronary artery bypass graft 
(CABG) or a  percutaneous coronary intervention 
(PCI) (48.6%, p = 0.07) and malignancies (51.4%, 
p = 0.03). It was also estimated that following RYR 
treatment for 4 years, the number needed to treat 
(NNT) to prevent one coronary event, one coro-
nary death and one mortality due to all causes in 
elderly patients were respectively 18, 33 and 23. In 
adults, however, these numbers were 23, 82 and 
51. Side effects were not significantly different be-
tween the groups [93].
Safety: Inhibitors or inducers of CYP450 may 
cause alterations of plasma concentrations of 
MonK. In fact, the concomitant use of some nu-
traceuticals (such as grapefruit juice) [94], food 
or drugs (cyclosporine, niacin, fibrates, coumarin, 
verapamil, antifungals, macrolides, nefazodone, 
HIV protease inhibitors [93]), which are CYP450 
inhibitors may increase the risk of myotoxic side 
effects and in some rare cases cause rhabdomy-
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olysis [95]. While the chronic administration of 
monacolins could be responsible for mild to mod-
erately severe side effects, it is usually well toler-
ated. However, serious attention must be paid to 
citrinin, a mycotoxin metabolite derived from the 
fermentation of Monascus [96]. The chronic inges-
tion of citrinin is nephrotoxic in various animal 
species, gradually leading to hyperplasia of the 
renal tubular epithelium, renal adenomas and in 
some cases to renal tumors (at a dose of 50 mg/kg 
body weight (b.w.) causing tumors in 100% of 
the animals tested). Moreover, citrinin induces 
reproductive toxicity, malformations and proven 
embryo toxicity in vitro and in vivo [97–99]. The 
EFSA has established as 0.2 μg/kg b.w. per day 
the highest quantity of citrinin which can be tak-
en by humans with no nephrotoxic effects [100]. 
However, at these doses genotoxic and carcino-
genic effects are not excluded. In the market RYR 
supplements were detected with levels of citrinin 
exceeding 114 μg/capsule and for 4 capsules/day 
(recommended dosage) the mean was 456 μg/
day of citrinin, which is well above the level of 
20 μg/kg b.w. per day suggested by the EFSA [86].
In summary, the administration of RYR can be 
recommended because of its effects on LDL-C in 
patients with moderately elevated cholesterol, es-
pecially in primary prevention. On the basis of the 
available evidence, the EFSA has expressed a sci-
entific opinion on the substantiation of health 
claims about the relationship between admin-
istration of RYR and the maintenance of plasma 
LDL-C levels – the relationship is possible using 
a  dose of RYR which contains 10 mg of MonK 
(maximum daily dose in Europe as dietary supple-
ment) [101]. However, some National Regulatory 
Agencies in Europe have recently suggested using 
lower dosages of MonK for safety purposes. More-
over, specific attention has to be given when full 
dosed RYR is administered in previously statin-in-
tolerant subjects.
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
I A 3–10 mg 
(mona-
colin K)
–15% to 
–25%
↓ ApoB, 
hs-CRP, 
MMP-2, 
MMP-9
↑ FMD,  
↓ PWV
↓ CV 
events 
in sec-
ondary 
preven-
tion
3.2. Garlic (Allium sativum)
Mechanism of action: Garlic (Allium sativum) 
is a  nutraceutical known for its multiple health 
properties. One of the most important molecules 
present in garlic is allicin (diallyl thiosulfinate) pro-
duced from the non-proteinogenic amino acid alli-
in (S-allyl cysteine sulfoxide) in a reaction catalyzed 
by alliinase [102]. Allicin could be one of the chem-
ical entities responsible for the garlic lipid-lower-
ing mechanism of action. In fact, it seems to be an 
inhibitor of HMG-CoA reductase, squalene-monoo-
xygenase and acetyl-CoA synthetase enzymes. Alli-
cin contains a thiol group, so it is also possible that 
it reacts with non-acetylated-CoA directly, reducing 
acetyl-CoA available for endogenous synthesis of 
cholesterol [103]. Other suggested mechanisms 
of action of garlic are blocking the absorption of 
dietary cholesterol and fatty acids and increased 
excretion of bile acids. However, further studies are 
necessary to finally confirm these effects and the 
molecules responsible for these possible lipid-low-
ering activities [104].
Efficacy: In a meta-analysis of 39 RCTs enroll-
ing 2298 mild-to-moderate hypercholesterolemic 
subjects the consumption of garlic extracts for at 
least 2 months showed a reduction of LDL-C (–0.23 
mmol/l (9 mg/dl), more evident in individuals with 
TC < 5.17 mmol/l (200 mg/dl) at baseline) [103]. 
The same author highlighted the beneficial effect 
on blood pressure of garlic [105], while Jung et al. 
[106] underlined that it is able to reduce apoB and 
increase the LDL/Apo B ratio. According to a recent 
meta-analysis of RCTs, garlic seems not to have 
any effect on lipoprotein (a) (Lp(a)) level [107]. Fi-
nally, garlic might exert a  significant antiplatelet 
activity in humans [108]. In conclusion, garlic at 
a dose of 6 g/day (depending on the percentage 
of allicin) could be useful in the management of 
mild cholesterolemia, probably more for the paral-
lel anti-hypertensive and anti-platelet effect than 
for the lipid-lowering one. The high doses required 
and the common aftertaste could limit the long-
term compliance with treatment.
Safety: Side effects are usually minimal (mostly 
gastrointestinal) and the extracts are well tolerat-
ed [104]. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIa A 5–6 g 
(extract)
–5% to 
–10%
↓ Blood 
pressure, 
platelet 
aggrega-
tion
Not 
demon-
strated
3.3. Pantethine
Mechanism of action: Pantethine, a  dimeric 
form of pantetheine, produced from pantothenic 
acid (vitamin B5) by the addition of cysteamine, 
has been widely tested for lipid-lowering activ-
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ity. In vitro it inhibits fatty acid synthesis and 
HMG-CoA reductase [109, 110]. Several human 
trials have confirmed these effects in humans 
[111, 112].
Efficacy: Recently a 16-week triple-blinded RCT 
carried out on 120 subjects with low to moderate 
CVD risk was published [113]. The authors showed 
that following an adequate diet in comparison 
with placebo, pantethine 600–900 mg/day demon-
strated significant (p < 0.005) and sustained re-
ductions (from baseline to week 16) in TC (3% – 
0.16 mmol/l (6 mg/dl)), LDL-C (4% – 0.10 mmol/l 
(4 mg/dl)) and apoB (5% – 0.0001 mmol/l (4 mg/
dl)). The data suggest that pantethine supplemen-
tation for 16 weeks (600 mg/day for weeks 1–8 
then 900 mg/day for weeks 9–16) is safe and sig-
nificantly lowers TC and LDL-C (although with rel-
atively limited clinical relevance) over and above 
the effect of therapeutic lifestyle changes (TLC) or 
diet alone [114]. In a further 16-week triple-blind-
ed RCT carried out on mildly hypercholesterolemic 
subjects pantethine 600–900 mg/day reduced 
LDL-C level by 11% [115].
Safety: The tolerability of pantethine is over-
all high, with acceptable safety confirmed also in 
children [114] and patients in hemodialysis [116].
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIa A 600–900 
mg 
Not ap-
plicable 
Not 
demon-
strated
Not 
demon-
strated
3.3. Bergamot (Citrus bergamia)
Mechanism of action: Bergamot is the common 
name of the fruit Citrus bergamia Risso and differs 
from other Citrus fruits in its composition, particu-
larly rich in flavonoids (as neoeriocitrin, neohesper-
idin, naringin, rutin, neodesmin, rhoifolin, poncirin) 
[117]. In particular, the 3-hydroxy-3-methyl-glutaryl 
flavanone enriched fraction (HMGF: brutieridin, 
melitidin and HMG-neoeriocitrin) has been extract-
ed from the bergamot peel; they act as statins by 
inhibiting HMG-CoA reductase and ACAT, reducing 
the formation of cholesterol esters and limiting the 
transport of cholesterol in the blood. Bergamot also 
contains naringin: like neoeriocitrin, melitidin and 
rutin it inhibits the oxidation of LDL-C, initiates ad-
enosine-monophosphate-kinase (AMPK) and has 
shown scavenging activity, suggesting a  possible 
preventive antiatherosclerotic mechanism. It is also 
possible that bergamot increases the fecal excre-
tion of cholesterol, reducing the intestinal absorp-
tion and increasing the turnover and excretion of 
bile acids [118, 119].
Efficacy: Clinical studies on the lipid-lowering 
properties of bergamot are still very few. The study 
by Gliozzi et al., a prospective, open-label, parallel 
group, placebo-controlled trial, involved 77 patients 
with mixed dyslipidemia divided into 5 groups: pla-
cebo (n = 15), rosuvastatin 10 mg (n = 16), rosu-
vastatin 20 mg (n = 16), bergamot 1000 mg (ber-
gamot derived polyphenolic fraction, BPF) (n = 15), 
and bergamot 1000 mg + rosuvastatin 10 mg (n = 
15). After 4 weeks of treatment, LDL-C decreased 
from a baseline value of 4.94 mmol/l (191 ±3 mg/
dl) to a value of 2.97 mmol/l (115 ±4 mg/dl) (level 
of reduction: –1.96 mmol/l/75.8 mg/dl) after rosu-
vastatin 10 mg, to 2.26 mmol/l (87.3 mg/dl) (–2.69 
mmol/l/104 mg/dl) after rosuvastatin 20 mg, 2.92 
mmol/l (113 ±4 mg/dl) (–2.02 mmol/l/78.1 mg/dl) 
after BPF 1000 mg, and 2.33 mmol/l (90 ±3 mg/
dl) (–2.61 mmol/l/100.9 mg/dl) after rosuvastatin 
10 mg + BPF 1000 mg/day. Moreover, the groups 
treated with BPF (either alone or in combination) 
experienced a  reduction of some biomarkers of 
vascular oxidative damage including malonyldial-
dehyde (MDA; one of the major aldehydes formed 
during lipid peroxidation) and oxidized LDLs [120]. 
The same author evaluated the effects of berga-
mot (1300 mg/day) in 107 patients (divided into 
two groups) with metabolic syndrome (MetS) and 
non-alcoholic fatty liver disease (NAFLD) during 120 
consecutive days. They found that the treated group 
experienced a marked reduction of small dense LDL 
(sdLDL) and TG, and increased HDL-C levels com-
pared to placebo. Moreover, this was accompanied 
by a significant reduction of serum glucose, trans-
aminases, g-glutamyl-transferase, and inflammato-
ry biomarkers such as hs-CRP and tumor necrosis 
factor-α (TNF-α) [121]. Moreover, the amount of 
atherogenic sdLDL significantly decreased (–35%), 
while large buoyant LDLs increased (+38%; both 
p < 0.05) compared to baseline levels. These data 
are important, and emphasize the potential use 
of bergamot for reducing CVD risk, knowing that 
elevated levels of sdLDL-C associated with NAFLD 
are associated with an increased CV risk [122]. 
A further study involved 237 patients divided into 
four groups: A (n = 104) – subjects with hypercho-
lesterolemia (LDL-C > 3.36 mmol/l (130 mg/dl)) 
treated with bergamot (500 mg/day for 30 days); 
B (n = 42) – patients with hyperlipidemia (hypercho-
lesterolemia and hypertriglyceridemia) treated with 
bergamot (1000 mg/day for 30 days); C (n = 59) 
– patients with MetS treated with placebo; and D 
(n = 32) – hyperlipidemic patients who stopped 
treatment with simvastatin because of side effects 
(cramps and increased serum levels of creatine ki-
nase (CK)), treated with bergamot (1500 mg/day for 
30 days) after a 60-day wash-out period. The results 
showed dose-dependent lipid-lowering action of ber-
gamot (groups A and B respectively LDL-C: –24.1% 
and –30.6%, TG: –28.2% and –37.9%, HDL-C: +22.3% 
and +40.1%, p < 0.001 for all) compared to baseline. 
Group C (placebo) did not show significant reductions 
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in serum cholesterol. Group D showed a reduction of 
LDL-C and TG (–25.0% and –27.6%, respectively; p < 
0.001 for all), without any side effects [123]. In sum-
mary, the evidence indicates that bergamot has lip-
id-lowering effects, both quantitative and qualitative, 
especially by reducing the levels of sdLDL and TG and 
significantly increasing HDL-C levels. This suggests 
a potential use of bergamot in hypercholesterolemic 
and/or hypertriglyceridemic patients, intolerant to 
statins, with NAFLD and MetS. The main limitation 
of the evidence on bergamot efficacy is related to 
the fact that the greater part of the clinical literature 
has been provided by a single research unit and not 
confirmed elsewhere. Moreover, data on vascular 
parameters such as endothelial function and arterial 
stiffness are not available yet.
Safety: Clinical studies conducted to date with 
dosages between 500 and 1500 mg/day showed 
a good safety profile, with no side effects detected. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIa B 500–
1000 mg 
(BPF)
–15% to 
–40%
↓ sdLDL, 
hs-CRP, 
TNF-α
Not 
demon-
strated
3.4. Policosanols
Mechanism of action: Policosanols are aliphat-
ic primary alcohols mainly extracted from sugar-
cane (Saccharum officinarum L) wax. The inter-
est in policosanols has increased based on early 
Cuban studies, indicating the lipid-lowering and 
antiplatelet effects of this nutraceutical [124]. Pol-
icosanols have demonstrated inhibitory action on 
HMG-CoA reductase and on bile acid absorption, 
in addition to an activating effect on AMPK (in-
crease of fatty acid β-oxidation) [125].
Efficacy: In recent years several clinical stud-
ies have suggested a  reducing action of this nu-
traceutical on lipid profile, but the results are of-
ten non-significant. The study by Berthold et al. 
showed that the administration of policosanols in 
hypercholesterolemic patients does not statistical-
ly improve the levels of TC, TG, HDL-C and LDL-C. 
This trial included 143 subjects divided into five 
groups each treated with 10, 20, 40, 80 mg of pol-
icosanols or placebo. Nobody in any group at the 
end of the study (12 weeks) showed a  reduction 
of more than 10% in LDL-C [126]. These data were 
confirmed by the study of Backes et al., where 
policosanols did not significantly change the lipid 
profile of hypercholesterolemic subjects in either 
of the two treatment groups (treated with polico-
sanol or policosanol in addition to statin therapy) 
or placebo compared to the control [127]. Neither 
policosanols from rice nor wheat germ showed any 
significant effect on LDL-C, HDL-C, TG, oxLDL, apoB, 
Lp(a), homocysteine, CRP, fibrinogen or blood co-
agulation factors [128, 129]. There are several clin-
ical studies demonstrating the efficacy of combi-
nations containing policosanol also in association 
with other nutraceuticals (such as fermented red 
rice, berberine), but the role of the lipid-lowering 
effect of policosanol in these combinations is not 
clear. Based on all these data, policosanol should 
not be recommended in clinical practice until new 
well-designed studies are performed that defini-
tively clarify its lipid-lowering potential effect. 
Safety: The tolerability of policosanols is usual-
ly very good.
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
III A 10–80 
mg 
Non-sig-
nificant
None Not 
demon-
strated
4. Inducer of LDL-cholesterol excretion
4.1. Berberine
Mechanism of action: Berberine (BBR) is a qua-
ternary benzylisoquinoline alkaloid present in the 
root, rhizome, stem, fruit and bark of various spe-
cies of plants including Coptis (Coptis chinensis, 
Coptis japonica), Hydrastis (Hydrastis canadensis) 
and Berberis (Berberis aristata, Berberis vulgaris, 
Berberis croatica) [130]. The findings of the lipid- 
lowering effect of berberine are relatively recent. 
The mechanisms by which BBR regulates plasma 
cholesterol levels are essentially two: first, it is an 
inhibitor of proprotein convertase subtilisin/kex-
in type 9 (PCSK9) through the ubiquitination and 
degradation of hepatocyte nuclear factor 1α (HNF-
1α), causing increased levels and limited degrada-
tion of the hepatic LDL receptor (LDLR). Second, 
BBR acts directly on the expression of LDLR via 
two identified mechanisms, causing up-regulation 
of the receptors through a  post-transcriptional 
mechanism that stabilizes their mRNA (activation 
of extracellular signal regulated kinases (ERK) and 
Jun amino-terminal kinase (JNK)-dependent path-
ways) [131, 132]. BBR also has some secondary 
mechanisms of action; recent studies have em-
phasized that it reduces the intestinal absorption 
of cholesterol, increasing the fecal excretion and 
promoting the hepatic cholesterol turnover and 
the formation of bile acids [133]. Moreover, BBR 
is an activator of AMPK, which determines an in-
crease of fatty acid oxidation and a  reduction of 
the expression of lipogenic genes. Finally, it is an 
effective inhibitor of nicotinamide adenine di-
nucleotide phosphate (NADPH) oxidase-mediat-
ed oxidative stress [134, 135]. It is important to 
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emphasize that BBR is just one of the alkaloids 
present in the plants; it is therefore possible that 
some pleiotropic activities (such as antioxidant, 
anti-inflammatory, insulin sensitizer) might be due 
to some other substances and not only BBR. In Ber-
beris vulgaris alone, in addition to berberine, the 
following compounds have been have been identi-
fied: alkaloids – acanthine, bargustanine, berbam-
ine, berberrubine, beriambine, bervuleine, colum-
bamine, jatrorrhizine, lambertine, magnoflorine, 
palmatine, thaliemidine; vitamins – ascorbic acid, 
vitamin K, β-carotene; and tannins, flavonoids and 
flavanols, triterpenes, and coumarins [136]. The 
bioavailability of BBR is lower than 1%. This is due 
to the poor intestinal absorption (56%), caused by 
a  self particulate aggregation which reduces the 
solubility in the gastrointestinal tract, to the low 
permeability of the molecule (Biopharmaceutical 
Classification System (BCS) class III) and to the in-
testinal and liver first-pass metabolism (43.5% and 
0.14%, respectively) [137]. The effect of the intes-
tinal first pass is still unclear, but it is probably of 
enzymatic origin including CYP2D6 and CYP3A4 in 
liver metabolism. Finally, BBR is also the substrate 
of the efflux pump P-glycoprotein (P-gp). There-
fore in recent years alternative approaches have 
been studied to increase the bioavailability of BBR, 
using permeability enhancers (sodium caprate, 
sodium deoxycholate, chitosan), P-gp inhibitors 
(silymarin), or modified release dosage forms (na-
noemulsions, micelles, liposomes, nanoparticles), 
with quite satisfactory results.
Efficacy: The lipid-lowering efficacy of BBR has 
been confirmed by a recent meta-analysis that in-
cluded 27 clinical studies with 2569 participants. 
The effects of berberine on lipids were: LDL-C: 
–0.65 mmol/l (95% CI: –0.75; –0.56, p = 0.00001) 
(25.14 mg/dl); TG: –0.39 mmol/l (95% CI: –0.59; 
–0.19, p = 0.0001) (34.5 mg/dl); HDL-C: 0.07 mmol/l 
(95% CI: 0.04; 0.10, p = 0.00001) (2.71 mg/dl). 
These effects seem to be additive to those of 
statins and associated with a positive impact on 
glucose metabolism and blood pressure as well 
[138]. A recent study enrolled 130 patients under-
going PCI, randomized to two groups, and treat-
ed with BBR 600 mg/day or placebo in addition 
to standard therapies. The BBR group showed 
a marked reduction in TG (26% BBR vs. 13% con-
trol; the difference did not reach statistical signifi-
cance due to large inter-individual variations) and 
LDL-C (24% vs. 17% BBR control: p < 0.001) com-
pared to the control group. In addition, both groups 
showed a reduction in the levels of interleukin 6 
(IL-6) and monocyte chemoattractant protein-1 
(MCP-1) (p < 0.05 for each), as well as hs-CRP, in-
tercellular adhesion molecule-1 (ICAM-1), vascu-
lar cell adhesion molecule-1 (VCAM-1), and matrix 
metallopeptidase 9 (MMP-9) (p < 0.001 for all) 
compared to baseline. The levels of MMP-9, ICAM-1 
and VCAM-1, after 1 month, were significant-
ly reduced to a  greater extent in the BBR group 
compared to the control and baseline (p < 0.05) 
[137]. In summary, the use of BBR at doses rang-
ing between 500 and 1500 mg has proved to be 
effective in lipid lowering and relatively safe both 
in primary and secondary prevention. Compared to 
nutraceuticals with a statin-similar mechanism of 
action, BBR has a greater effect in the reduction of 
triglyceridemia, partly related to its positive effect 
on insulin-resistance [139]. Its use can therefore 
be recommended, especially in patients intolerant 
to statins, with mild hypercholesterolemia and in 
patients with MetS.
Safety: Based on the abovementioned data, 
side effects are mild to moderate, mostly gastroin-
testinal (diarrhea, constipation, abdominal disten-
sion) and comparable to the control groups [139]. 
No significant differences were detected in the 
levels of aspartate transaminase (AST), alanine 
transaminase (ALT), and creatinine in comparison 
to the control group [140]. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
I A 500–
1500 mg 
–15% to 
–20%
↓ ApoB, 
TG,  
hs-CRP, 
IL-6, 
MCP-1, 
ICAM-1, 
VCAM-1, 
MMP-9, 
glucose, 
HOMA 
index, 
blood 
pressure
Not 
demon-
strated
4.2. Green tea extracts
Mechanism of action: Some available RCTs on 
green tea suggest that its consumption could 
be protective against CHD and CVD [140]. Green 
tea is particularly rich in antioxidants such as 
polyphenols (up to 35% of dried weight) that 
are well-known cardioprotective compounds. 
The major fraction of polyphenols in green tea 
is catechins, structurally flavan-3-ols. The most 
important one is the epigallocatechin-3-gallate 
(EGCG), known for its antioxidant and cardiopro-
tective properties. It is possible that beyond the 
antioxidant effects derived from polyphenols and 
the reduction of lipid peroxidation, green tea in-
terferes with micellar solubilization and absorp-
tion of cholesterol. Green tea is an activator of 
AMPK (stimulating lipogenesis) and an HMG-CoA 
reductase inhibitor. Tea catechins have been re-
ported to have an inhibitory effect on the ileal 
apical sodium-dependent bile acid transporter 
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(reducing reabsorption of bile acids) to enhance 
the hepatic LDL-R expression and the biliary ex-
cretion of cholesterol [141, 142].
Efficacy: A meta-analysis of 20 RCTs and 1536 
participants showed a  reduction of LDL-C (mean 
difference (MD): –0.19 mmol/l (7.35 mg/dl); 95% CI: 
–0.3; –0.09, p = 0.0004). The lipid-lowering effects 
of green tea were found to be greater in RCTs with 
longer duration. Moreover, green tea extract exerts 
a mild but significant antihypertensive effect. The 
tested daily doses ranged from 250 to 1200 mg of 
green tea extract or from 170 to 850 mg of EGCG 
[143]. Moreover, green tea is associated with an im-
provement in FMD [144] and pulse wave velocity 
(PWV) [145], despite no apparent effect on hs-CRP 
levels [146]. Therefore, overall the consumption of 
green tea might be associated with a  decreased 
risk of CVD morbidity and mortality [147]. There 
are also no data on its influence on TG and HDL-C.
Safety: Usually the consumption of green tea is 
well tolerated; however, in some cases rash, tran-
sient elevation of blood pressure and mild gas-
trointestinal disorders may occur. Moreover, high 
doses of green tea can cause a deficiency of iron 
and folate due to its capacity to bind and reduce 
their intestinal absorption. Therefore, particular 
attention should be given to green tea consump-
tion during pregnancy [143].
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIa A 25– 
100 g 
–5% ↓ Blood 
pressure
↑ FMD, 
↓ PWV 
(tea)
4.3. Soy and lupin proteins
Mechanism of action: Preclinical and clinical 
evidence supports the positive effects of soy and 
lupin proteins on lipid profile. Generally, it is be-
lieved that bioactive peptides present in soy and 
lupin (such as conglutin-g) may be responsible for 
the lipid-lowering effect of these legumes [148]. 
However, the isoflavones could contribute to this 
effect as well [149]. The cholesterol-lowering 
mechanisms proposed for soy and lupin seem to 
be numerous but are still unclear, including the 
down-regulation of the expression of the hepatic 
transcription factor of sterol regulatory element 
binding protein (SREBP-1) (via PI3K/Akt/GSK3β 
pathways, with decreased hepatic lipoprotein se-
cretion and cholesterol content), the regulation of 
SREBP-2 (with increased clearance of cholesterol 
from the blood), the reduction of cholesterol syn-
thesis, the increase of apoB receptor activity or 
the increase of the fecal excretion of bile salts 
[150–153].
Efficacy: Several meta-analyses of RCTs have 
underlined the cholesterol-lowering properties of 
soy. In particular, a recent one including 35 RCTs 
and 2670 subjects concluded that soy proteins 
(in particular B-conglycinin globulin) have a cho-
lesterol-lowering effect with a mean reduction in 
LDL-C of 3% (–0.12 mmol/l/4.6 mg/dl), TC of 2% 
(–0.14 mmol/l/5.4 mg/dl) and TG of 4% (–0.06 
mmol/l/5.3 mg/dl) and is able to increase HDL-C 
by 3% (+0.04 mmol/l/1.6 mg/dl), the effect being 
proportional to the baseline LDL-C level [154]. The 
mean tested dose was 30 g/day.
If isoflavones seem not to add significantly 
to the lipid-lowering effect of soy proteins, they 
seem to have direct positive effects on endothelial 
function [155] and arterial stiffness [156].
Yellow lupine (Lupinus luteus) is composed of 
proteins (30–35%), fibers (30%), carbohydrates 
(3–10%) and fat (6%, of which 81% is unsaturat-
ed); in addition, there are both macro-elements (in-
cluding phosphorus, calcium and magnesium) and 
microelements (including zinc, copper, chromium 
and cobalt) [157]. One aspect that differentiates 
lupin from other legumes is the absence of phy-
toestrogens, low sodium content and low glycemic 
index. In a randomized cross-over study, 33 hyper- 
cholesterolaemic subjects (TC > 6.6 mmol/l/ 
255 mg/dl) were included and treated for 8 weeks 
with 25 g/day of lupin protein isolate (LPI) fol-
lowed by 4 weeks of washout and 8 weeks of 
treatment with milk protein isolate (MPI). Com-
pared to baseline, a significant reduction of LDL-C 
was already observed in both groups after 4 weeks 
(–12%, p < 0.008). In the LPI group, the levels of 
HDL-C increased significantly (p < 0.036) and the 
LDL/HDL ratio decreased (p = 0.003), compared to 
the MPI group [158]. These results were confirmed 
by the same author in the next randomized, con-
trolled, double-blind three-phase crossover trial, 
including 72 patients with hypercholesterolemia 
treated for 28 days with LPI, MP (milk protein) or 
MPA (milk protein 1.6 g/day of arginine). In ad-
dition to reducing LDL-C levels (in MPA and LPI 
groups), the LPI group showed an improvement 
in the levels of homocysteine (compared to the 
MPI and MPA groups), uric acid and TG [159]. The 
cholesterol-lowering properties of lupin were also 
highlighted in a third RCT proving a reduction of 
LDL-C (–12%) comparable to the studies described 
previously [160]. It is also worth mentioning that 
exposure to isoflavone-containing soy products 
modestly, but significantly, improved endothelial 
function, as demonstrated in a  meta-analysis of 
17 RCTs [155].
In conclusion, the intake of soy and lupine rep-
resents a potential, relatively weak adjuvant ther-
apy in the treatment of hypercholesterolemia, es-
pecially in individuals with moderate cholesterol 
levels. 
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Safety: The chronic use of a high quantity of 
soy products containing isoflavones could inter-
fere with thyroid function and fertility. Further-
more, soybean and its derivatives contain high 
amounts of phytic acid that reduces the absorp-
tion of minerals such as calcium, magnesium, 
copper, iron and zinc. Lupine has shown a good 
safety profile, causing no severe side effects, 
and those which occurred were mostly gastroin-
testinal. The large amount of vegetable proteins 
which have to be taken in order to obtain a sig-
nificant LDL-C reduction could decrease patient 
compliance in the long term and should be ac-
companied by an attentive balance of the other 
dietary sources of proteins.
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIb A 25– 
100 g 
–3% to 
–10%
Not 
demon-
strated 
in hu-
mans
↑ FMD 
(soy 
with 
isofla-
vones)
5. Other nutraceuticals with mixed 
mechanisms of action
5.1. Polyunsaturated ω-3 fatty acids
Omega-3 (ω-3) fatty acids are polyunsaturat-
ed fatty acids (PUFAs) which contain a  double 
bond in position 3 at the end of the carbon chain. 
Natural sources of ω-3 are present both in animal 
(fish, krill, egg, squid) and plant (algae, flaxseed, 
walnut, edible seeds, clary sage, seed) sources 
[161]. In recent years the EFSA, the AHA and the 
Food Standards of Australia and New Zealand 
(FSANZ) organizations have recognized ω-3 fatty 
acids as preventive nutraceuticals for CVD [27]. 
EFSA established a claim in 2010 indicating that 
the intake of at least 2 g/day of docosahexae-
noic acid (DHA) and eicosapentaenoic acid (EPA) 
has the ability to maintain normal blood TG lev-
els [162, 163]. The AHA has indicated doses from 
2 to 4 g/day of EPA/DHA to reduce TG levels by 
25–30% [164]. All these guidelines agree about 
the high safety of PUFAs, despite the relatively 
frequent fishy aftertaste and occasional abdom-
inal discomfort.
Mechanism of action: The mechanisms 
through which ω-3 reduce TG are: the reduction 
of synthesis of hepatic VLDL, the reduction of 
available substrate for the synthesis of new TG 
(ω-3 are false substrates), the reduction of the 
activity of TG-synthesizing enzymes (diacylglyc-
erol acyltransferase or phosphatidic acid phos-
phohydrolase), the increase of β-oxidation of 
fatty acids, the reduction of the endogenous syn-
thesis of fatty acids and the increase of synthesis 
of phospholipids [165].
Efficacy: EFSA health claims and the statement 
of the AHA are supported by a  large number of 
RCTs. The meta-analysis of Eslick et al. included 
47 RCTs with 16 511 participants with hypercho-
lesterolemia to assess the effects of the average 
daily dose of 3.25 g of EPA/DHA for 24 weeks. The 
results showed a  significant reduction in TG of 
14% (–0.34 mmol/l (30.12 mg/dl), 95% CI: –0.41; 
–0.27). In addition, there was a small insignificant 
reduction of LDL-C of 0.06 mmol/l (2.3 mg/dl), but 
no differences in HDL-C [166]. These results were 
confirmed in normolipidemic and borderline sub-
jects in the meta-analysis by Leslie et al. that in-
cluded 2270 individuals with optimal lipid or sub- 
optimal TG profiles (TG < 2 mmol/l (177 mg/dl)). 
In studies that used more than 4 g/day of ω-3 
TG were reduced by 9–26%, while a reduction of 
4–51% was found with doses from 1 to 5 g/day 
of ω-3 [167]. A dose-dependent effect of ω-3 was 
also observed by Di Stasi et al. with additional 
benefits obtainable for lipid profile when supple-
mentation of ω-3 was raised as high as 4.9 g/day 
[168]. It was also observed that the administra-
tion of EPA or DHA individually gave comparable 
effects in the reduction of TG, but not other lipid 
parameters; in fact, DHA showed a very modest 
reduction of LDL-C by 5% and slightly increased 
HDL-C, while EPA produced no significant chang-
es [169, 170]. PUFAs might also be associated 
with an improvement of FMD and PWV, and, with 
larger dosages, with positive effects on inflamma-
tory diseases and mood [171]. Moreover, in the 
large long-term Gruppo Italiano per lo Studio del-
la Sopravvivenza nell’ Infarto miocardico (GISSI) 
Prevenzione trial that involved 11 324 patients 
surviving recent MI, supplementation with 1 g 
of EPA/DHA significantly reduced the risk of CV 
death [172]. 
A  rich source of ω-3 PUFAs is krill (Euphausia 
superba), a small crustacean that lives in the Ant-
arctic Ocean, containing many types of long-chain 
PUFAs. The ω-3 present in krill oil (EPA + DHA) ap-
pears to be better absorbed in the gastrointestinal 
tract than that found in fish oil: this is possible 
because of phosphatidylcholine (the main phos-
pholipid present in krill (40%), which binds EPA 
and DHA), which confers greater stability to fatty 
acids. In addition, krill oil is rich in antioxidants, 
including vitamin E and astaxanthin [173]. There-
fore, at the same dose, krill oil appears to be more 
effective than fish oil in the adjustment of lipid 
profile. Ulven et al. reported that the effects on 
the reduction of TG of a dose of 543 mg of DHA 
and EPA contained in krill oil are comparable to 
doses of 2.66 g of EPA and DHA present in fish oil 
[174]. Similar data were obtained by Cicero et al. 
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[175]. In the most recent meta-analysis of 7 RCTs 
with 662 participants Ursoniu et al. found a sig-
nificant reduction in plasma concentrations of 
LDL-C (–15.52 mg/dl (0.4 mmol/l); 95% CI: –28.43 
to –2.61; p = 0.018), and TG (–14.03 mg/dl (0.16 
mmol/l); 95% CI: –21.38 to –6.67; p < 0.001), and 
significant elevation in plasma concentrations of 
HDL-C (6.65 mg/dl (0.17 mmol/l); 95% CI: 2.30 to 
10.99; p = 0.003) following supplementation with 
krill oil [176]. 
Controversial results were obtained with α-lin-
olenic acid (ALA), an ω-3 fatty acid found in many 
vegetable oils (such as olive and flaxseed oil). Nev-
ertheless, a  rich source of ALA, the flaxseed (Li-
num usitatissimum, ALA = 50–62% of flaxseed oil 
or 22% of whole flaxseed), an oilseed crop grown 
on all continents, showed lipid-lowering activity 
regarding LDL-C (–0.08 mmol/l). This effect may 
be explained by the other components of flaxseed 
including lignans (0.2–13.3 mg/g flaxseed) and 
soluble fibers (25% of total weight) that could en-
hance the reduction of total cholesterol. The cho-
lesterol-lowering effects were more significant in 
females (in particular in postmenopausal women) 
and in individuals with high cholesterol levels at 
baseline [177]. Flaxseed seems also to exert a mild 
but significant antihypertensive effect [178]. The 
available data suggest that the consumption of 
flaxseed is safe and well tolerated. Another veg-
etal source of essential fatty acids is sesame. 
A recent meta-analysis of RCTs showed that ses-
ame fractions intake is associated with a  signif-
icant TG reduction (–0.24 mmol/l (21.3 mg/dl); 
95% CI: –0.32; –0.15, p < 0.001), while no changes 
occurred with LDL-C or HDL-C levels [179].
In conclusion, omega-3 EPA and DHA represent 
a valid nutraceutical to reduce TG in the blood (by 
18–25%) while their effects on LDL-C and HDL-C 
are clinically insignificant. However, it has to be 
stressed that CVD outcome studies with ω-3 have 
produced inconsistent results and their clinical ef-
ficacy appears to be related to non-lipid effects. 
Especially, it needs be noted that smaller doses 
than 2–4 g/day such as a low dose supplementa-
tion of a margarine with n-3 PUFAs (400 mg/day 
EPA + DHA) or α-linolenic acid (2 g/day) do not 
significantly reduce TG levels, as was confirmed in 
an RCT involving 4837 post-MI patients. Such sup-
plementation also did not reduce the rate of major 
CVD events [180]. A relatively recent meta-analy-
sis including data from 63 030 patients from 20 
clinical trials showed that treatment with ω-3 did 
not have an impact on a composite CVD endpoint 
or total mortality but was associated with a sig-
nificantly decreased rate of vascular death [181].
Safety: No serious side effects have been re-
ported; most of them have been defined as mild 
gastrointestinal [169]. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
I A 1–4 g Not ap-
plicable 
↓ sdLDL, 
TG, 
hs-CRP, 
TNF-α,  
↓ ad-
hesion 
mole-
cules, 
↓ blood 
pressure
↑ FMD,  
↓ PWV,  
↓ post- 
myocar-
dial in-
farction 
sudden 
death 
risk 
5.2. g-oryzanol
Mechanism of action: Another nutraceutical 
with a  potential effect on lipid profile is gam-
ma-oryzanol (g-oryzanol) from rice brain oil [182]. 
g-oryzanol is a mix of triterpene alcohol and sterol 
ferulates with lipid-lowering actions by the inhi-
bition of HMG-CoA reductase and the reduction 
of intestinal cholesterol absorption [183]. To date 
in Korea at least 16 varieties of rice bran oil, con-
taining different percentages of g-oryzanol (26.7 
to 61.6 mg/100 g), have been identified [184]. 
Efficacy: The lipid-lowering effects of this nu-
traceutical have been shown in in vitro and in vivo 
studies (in animals and humans); however, it re-
mains unclear what are the dosages to be used 
in clinical practice, and what is the impact of 
g-oryzanol on vascular health [182]. A recent me-
ta-analysis of 11 RCTs showed that rice bran oil 
consumption resulted in a significant decrease in 
concentrations of LDL-C (–0.18 mmol/l (7 mg/dl), 
95% CI: –0.26; –0.09, p < 0.001). The increase in 
HDL-C levels was considerable only in men (0.17 
mmol/l (6.6 mg/dl); 95% CI: 0.06; 0.28, p = 0.002) 
[185]. 
Safety: Overall, no side effects have been regis-
tered with rice bran oil consumption [186].
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIb B 300 mg 
(g-oryza-
nol)
–5% to 
–10% 
↓ ApoB, 
↑ HDL-C
Not 
demon-
strated
5.3. Spirulina
Mechanism of action: Spirulina (Arthrospi-
ra platensis) is a  filamentous microalga with 
known lipid-lowering effects, but with an un-
clear mechanism of action [186]. Spirulina 
contains high amounts of antioxidants such as 
β-carotene, phycocyanin, microelements (K, Na, 
Ca, Mg, Fe, Zn), vitamins (tocopherols), amino 
acids, and PUFAs. C-phycocyanin, a  particular 
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essential pigment of Spirulina, contains a phy-
cocyanobilin, which can activate atheroprotec-
tive heme oxygenase-1 (HMOX-1), a key enzyme 
in the heme catabolic pathway in endothelial 
cells. Moreover, phycocyanin has proven antiox-
idant, anti-inflammatory and radical scavenging 
properties [187]. 
Efficacy: According to experimental studies in 
alloxan-injured mice, phycocyanin decreases TC 
and TG levels in serum, increases the hepatic gly-
cogen level and maintains glucokinase (GK) ex-
pression in the liver. A recent meta-analysis that 
included 7 clinical trials to assess the effect of spi-
rulina supplementation on plasma lipid concen-
trations showed the lipid-lowering efficacy of spi-
rulina, with a reduction of LDL-C by –1.07 mmol/l 
(41.32 mg/dl) (95% CI: –1.57; –0.57, p < 0.001), 
TC by 1.21 mmol/l (46.76 mg/dl) (95% CI: –1.74; 
–0.68, p < 0.001) and TG by –0.5 mmol/l (44.23 
mg/dl) (95% CI: –0.57; –0.43, p < 0.001) and an 
increase of HDL-C of +0.16 mmol/l (6.06 mg/dl) 
(95% CI: 0.06; 0.25, p = 0.001) [188].
Safety: Spirulina is considered to be one of 
the most healing and prophylactic ingredients of 
nutrition in the 21st century due to its nutrient 
profile, lack of toxicity and therapeutic effects. Ac-
cording to the available data it seems to be very 
well tolerated. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIa B 400– 
800 UI
–5% ↓ TG,  
↑ HDL-C
Not 
demon-
strated
5.4. Curcumin
Mechanism of action: Curcumin is the major 
phenolic compound present in the spice turmeric 
(in the rhizome of Curcuma longa, curcuminoids 
constitute approximately 5% of the weight), 
associated with different properties including 
lowering plasma cholesterol, antioxidant and an-
ti-inflammatory effects [188]. Other polyphenolic 
molecules belonging to the class of curcuminoids 
are demethoxycurcumin and bisdemethoxycur-
cumin. As reported in recent meta-analyses of 
RCTs, curcuminoids showed an increase in serum 
activities of superoxide dismutase (p = 0.0007) 
and catalase (p = 0.005) and glutathione con-
centrations (p = 0.01) and a reduction in serum 
lipid peroxides (p = 0.008) [189] and of TNF-α 
[190]. The lipid-lowering mechanisms of action 
of curcuminoids are unclear; nevertheless, it 
seems that curcumin inhibits the expression of 
the NPC1L1 transporter via the SREBP2 transcrip-
tion factor [191], and that it increases the efflux 
of cholesterol via expression of ABCA1 and acti-
vating AMPK-SIRT1-LXRα signaling in THP-mac-
rophage-derived foam cells [192]. Furthermore, 
curcumin enhances the number of LDL-R and 
promotes LDL particle uptake through downreg-
ulation of the expression of PCSK9 [193]. In ad-
dition, epigenetic modulators such as microRNAs 
(miRs) have emerged as novel targets of curcum-
in [194].
Efficacy: Nevertheless, the results of RCTs re-
garding the effects of curcumin on lipid profile 
are still inconsistent; a meta-analysis by Sahebkar 
et al. showed no significant effects on LDL-C, 
HDL-C or TG when considering heterogeneous 
populations [195]. However, recently some avail-
able trials have provided more positive data. In 
a  study including MetS patients, treatment with 
1 g/day of curcuminoids as an add-on to the stan-
dard therapy resulted in a  significant reduction 
of LDL-C (–0.78 mmol/l (30 mg/dl), p < 0.001), TG 
(–0.2 mmol/l (17.7 mg/dl), p = 0.006), and Lp(a) 
(–0.286 μmol/l (8 mg/dl), p < 0.001) and an eleva-
tion of HDL-C (+0.18 mmol/l (7 mg/dl), p = 0.003) 
[196]. These data have since been confirmed in 
a  further trial carried out on 100 MetS patients 
[197] and in another one with 80 NAFLD patients 
[198]. In recent RCTs, supplementation with cur-
cumin (1 g/day) was associated with a reduction 
of serum uric acid (p < 0.001) [199], increase of 
adiponectin (+76.78%, p = 0.033) levels and re-
duction of leptin (–26.49%, p = 0.238) [189]. All 
these effects seem to be related to the main meta-
bolic effect of curcumin, which is an improvement 
of insulin resistance [200]. Finally curcumin con-
sumption is also associated with an improvement 
in FMD [201] and PWV [202].
Safety: Curcumin’s safety profile is good and 
well documented. Nevertheless, a major problem 
is its oral bioavailability: curcumin has low solubil-
ity in water and it is a substrate of rapid metab-
olism. New strategies of release have been stud-
ied and tested such as phytosomal complexation 
with phosphatidylcholine, coadministration of pip- 
erine, using turmeric oleoresin, reducing particle 
size, and changing the formulation (nanoemul-
sion, solid lipid nanoparticle, microencapsulation); 
however, in vivo data of these new formulations 
are lacking [203].
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects on 
other CV 
risk bio-
markers
Direct 
vascular 
effects
IIa B 1–3 g –5% ↓ TG, Lp(a), 
glucose, 
HbA1c, 
HOMA in-
dex, hs-CRP, 
TNF-α, IL-6, 
↑ adiponec-
tin, HDL-C
↑ FMD,  
↓ PWV
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5.5. L-carnitine
Mechanism of action: Carnitine is a hydrophilic 
quaternary amine that plays a number of essen-
tial roles in metabolism with the main function 
being the transport of long-chain fatty acids from 
the cytosol to the mitochondrial matrix for β-oxi-
dation [204]. 
Efficacy: L-carnitine has no effect on LDL-C lev-
els, but a meta-analysis of 7 RCTs including data 
from 375 patients showed a significant reduction 
of Lp(a) levels following L-carnitine supplemen-
tation (–0.31 μmol/l (8.82 mg/dl), 95% CI: –0.36; 
–0.27, p < 0.001) [205]. Moreover, L-carnitine 
seems to have a positive impact on body weight 
management [206]. In the most recent meta-anal-
ysis of 10 RCTs with 925 patients Mazidi et al. 
showed significant reduction of serum CRP and 
TNF-α concentrations following L-carnitine admin-
istration (–0.60 mg/l (5.71 nmol/l), 95% CI: –0.87 
to –0.32, and –0.36 pg/dl, 95% CI: –0.56 to –0.15, 
respectively) [207]. 
Safety: No safety concerns have been raised, 
but reliable safety data are still lacking. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIb B 1–2 g Not ap-
plicable 
↓ hs-CRP, 
↓ Lp(a), 
↓ body 
weight
Not 
demon-
strated
5.6.  Artichoke (Cynara scolymus, Cynara 
cardunculus)
Mechanism of action: According to some 
pre-clinical and clinical investigations, artichoke 
leaf extract (ALE) has potential hypolipidemic and 
hepatoprotective effects. The beneficial effects 
of artichoke can be attributed to its antioxidant 
action. The main substances are mono- and di-
caffeoylquinic acid (cynarin and chlorogenic acid), 
caffeic acid (1%), volatile sesquiterpene and fla-
vonoids (1%), which include the glycosides luteo-
lin-7β-rutinoside (scolymoside), luteolin-7β-D-glu-
coside and luteolin-4β-D-glucoside [208, 209]. The 
lipid-lowering mechanisms of artichoke seem to 
be essentially two: the interaction of luteolin with 
the HMG-CoA reductase enzyme and the path-
ways of regulation in the liver of sterol regulatory 
element-binding proteins (SREBPs) (paradoxically 
elevated in patients with non-alcoholic steatohep-
atitis (NASH)) and acetyl-CoA C-acetyltransferase 
(ACAT) [210]. 
Efficacy: An RCT (75 patients treated for 12 
weeks with 1280 mg/day of artichoke leaf ex-
tract or placebo) showed a mean reduction of TC 
by 4.2% compared to baseline and an increasing 
trend of TC levels in the placebo group. The to-
tal difference between the two groups was sta-
tistically significant (p = 0.0025). No significant 
difference between groups was observed for 
LDL-C, HDL-C or TG levels [211]. A  second RCT 
(143 patients treated with 1800 mg/day of ALE 
for 6 weeks) showed a mean reduction of TC of 
18.5% compared to 8.6% in the placebo group – 
the difference between the two groups was sta-
tistically significant (p < 0.00001). Moreover, the 
levels of LDL-C were also significantly decreased 
in the artichoke leaf extract group (mean: –1.26 
mmol/l (48.7 mg/dl)) compared to the place-
bo group (mean: –0.33 mmol/l (12.8 mg/dl), 
p < 0.00001). No differences were observed for 
other lipid parameters [212]. The third study 
(44 patients treated with 1920 mg/day of ALE for 
12 weeks) showed no significant differences in 
the lipid profile at the end of the treatment. How-
ever, according to a  subgroup analysis, patients 
treated with artichoke leaf extract who had at 
baseline TC levels greater than 230 mg/dl showed 
a significant reduction of TC when compared with 
those treated with placebo (p = 0.0015) [213]. In 
a recent RCT, 60 patients moderately hyperlipid-
emic and hypercholesterolemic with NASH were 
treated with 2700 mg/day of artichoke extract 
(6 tablets) or placebo for 2 consecutive months. 
The results showed a  significant reduction of 
LDL-C by 11.5% (p = 0.039) and TG by 20.1% 
(p = 0.011) compared to baseline. The most re-
cent meta-analysis of 9 RCTs with 702 subjects 
suggested a significant decrease in plasma con-
centrations of TC (weighted mean difference 
(WMD): –17.6 mg/dl (0.46 mmol/l), 95% CI: 
–22.0, –13.3, p < 0.001), LDL-C (–14.9 mg/dl 
(0.39 mmol/l), 95% CI: –20.4, –9.5, p = 0.011) 
and triglycerides (WMD: –9.2 mg/dl (0.1 mmol/l), 
95% CI: –16.2, –2.1, p = 0.011) [214]. In addition, 
artichoke extract showed pleiotropic activities in 
the improvement of certain liver enzymes such as 
AST and ALT (p < 0.001), blood sugar (p = 0.029) 
and systolic blood pressure (p = 0.004) [210]. 
Safety: In all studies reported to date no seri-
ous side effects have been detected, confirming 
the good tolerability and safety of artichoke leaf 
extract in the short-medium term. What is more, 
ALE exerts a hepatoprotective effect, and might be 
useful in statin-intolerant patients with elevated 
ALT levels. In some cases, there have been minor 
and transient gastrointestinal effects. Long-term 
safety studies are not available yet. In conclusion, 
ALE could represent an adjuvant in the regulation 
of lipid profile and liver levels of AST and ALT; 
however, the available clinical data are still pre-
liminary. Studies on vascular outcomes such as 
arterial stiffness and endothelial function are also 
needed. 
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Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIa B 1–3 g –5% to 
–15% 
↓ TG  
↓ AST, 
ALT, 
glucose
Not 
demon-
strated
5.7. Vitamin E
Mechanism of action: Vitamin E includes eight 
distinct chemical entities: α-, β-, g-, and δ-tocoph-
erol and α-, β-, g-, and δ-tocotrienol. The most 
studied is α-tocopherol, while other forms are 
poorly understood. There are several suggest-
ed mechanisms of lipid-lowering action of vita-
min E: peroxisome proliferator-activated receptor 
(PPAR-α, PPAR-β, and PPAR-g) activation, HMG-CoA 
reductase inhibition and radical scavenger [215]. 
Efficacy: Data from clinical trials are however 
disappointing, showing minimal effects of vitamin 
E on lipid pattern [216]. On the other hand, vita-
min E has shown a preventive action on CV risk. At 
doses between 50 and 200 mg it showed an im-
provement of endothelial function (reducing the 
serum levels of hs-CRP, advanced glycation end 
products, metalloproteinases and cell adhesion 
molecules) and arterial stiffness (improving PWV, 
pulse volume (PV) and the augmentation index 
(AI)) [217, 218]. Clinical studies are needed to fi-
nally clarify the conflicting results in the literature, 
the dosages (100 mg tocotrienols are different to 
100 mg of vitamin E and 100 mg of tocopherols) 
and vitamin E components, which have greater 
lipid-lowering efficacy. Even if vitamin E seems 
not to be an effective lipid-lowering treatment, 
its supplementation seems to be associated with 
reduced risk of fatal myocardial infarction [219]. 
Safety: In humans, doses of tocotrienols up to 
1000 mg/day have been reported as safe [220].
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIb B 400– 
800 UI
≤ –5% ↓ ApoB,  
↑ HDL-C
↑ FMD, 
↓ PWV, 
↓ risk of 
myo-
cardial 
infarc-
tion
5.8. Anthocyanins
Mechanism of action: Anthocyanins are flavo-
noid pigments found in leaves, stems, roots, flow-
ers, fruits and vegetables with dark color as blue-
berries, black rice, purple cabbage, raspberries, 
purple grapes and cherries. Among the biological 
activities exerted by anthocyanins, clinical trials 
have demonstrated particular antioxidant, anti-in-
flammatory and lipid-lowering effects [221]. 
Efficacy: In 58 diabetic patients, 320 mg/day of 
anthocyanins for 24 weeks significantly decreased 
LDL-C (–7.9%, p < 0.05), TG (–23%, p < 0.01), 
apoB48 (–16.5%, p < 0.05), and apoCIII (–11%, 
p < 0.01) and increased HDL-C (+19.4%, p < 0.05) 
compared to placebo. Moreover, the anthocyanin 
group showed an improvement of fasting plasma 
glucose (–8.5%, p < 0.05), of homeostasis model 
assessment (HOMA) for insulin resistance index 
(p < 0.05) and of adiponectin concentrations 
(+23.4%, p < 0.01) [222]. In addition to lipid-lower-
ing effects, anthocyanins are potent antioxidants, 
reducing the oxidative stress and inflammation; 
in humans maqui berry extract significantly de-
creased lipid peroxidation, urinary F2-isoprostanes 
and inflammatory mediators [223]. Epidemiological 
data suggest that higher dietary intakes of antho-
cyanins are associated with lower carotid-femoral 
PWV and carotid intima-media thickness [224]. 
Safety: Anthocyanins are well tolerated with-
out side effects at dosages ≤ 640 mg/day. Further 
studies are needed to assess the clinical efficacy 
of anthocyanins in different kinds of populations 
and to evaluate their vascular effects. Moreover, it 
will also be important to investigate the bioavail-
ability of these compounds and the efficacy and 
safety of their metabolites. In fact it is well known 
that the bioavailability of anthocyanins is low and 
they are rapidly biotransformed into derivates of 
phenolic acid [225].
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIb B 100– 
450 mg 
–5% to 
10%
↓ oxLDL, 
TG, 
glucose, 
HbA1c, 
HOMA 
index,  
↑ adi-
ponectin, 
HDL-C
Not 
demon-
strated
5.9. Silymarin (Silybum marianum)
Mechanism of action: Silymarin is a complex of 
flavonolignans of the fruit Silybum marianum con-
taining silybin, isosilybin, silydianin and silychris-
tin, four polyphenolic molecules with poor water 
solubility. It is known for its antioxidant and hepa-
toprotective properties and in recent years as an 
adjuvant in hyperlipoproteinemias [226]. Silymarin 
reduces lipid peroxidation of LDL by acting as 
chain breaking antioxidant by scavenging free rad-
icals and being associated with enzyme complexes 
such as superoxide dismutase and glutathione. 
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Efficacy: There are preliminary studies suggest-
ing a potential role of silymarin as lipid-lowering 
agent; studies in vitro have shown an inhibitory 
effect of silybin on HMG-CoA reductase and in 
vivo an improved uptake of LDL by the liver and 
a reduction of hepatic cholesterol synthesis [227]. 
Specific data on hypercholesterolemic patients 
are not available. In diabetic patients, silymarin 
improves fasting plasma glucose (FPG) and HbA
1c, 
but not lipid parameters [227]. 
Safety: Silymarin has low bioavailability. Fur-
ther investigations and combination studies are 
needed to improve the intestinal absorption of 
this molecule; e.g. in complex with phosphatidyl-
choline, silybin increases its bioavailability 10-fold. 
Safety data are still lacking.
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
III C NA –0% ↓ oxLDL, 
AST, ALT, 
gGT, 
glucose, 
HbA1c
Not 
demon-
strated
5.10. Conjugated linoleic acid
Mechanism of action: Conjugated linoleic acids 
(CLAs) are isomeric forms of linoleic acid, derived 
prevalently from the fatty tissues and milk of ru-
minant animals. CLA is both a trans fatty acid and 
a cis fatty acid [228]. 
Efficacy: In prospective observational stud-
ies, dietary linoleic acid (LA) intake is inverse-
ly associated with CHD risk in a  dose-response 
manner [229]. In a recent systematic review and 
meta-analysis, CLA supplementation was asso-
ciated with a  significant decrease in LDL-C (MD: 
–0.22 mmol/l (8.5 mg/dl); 95% CI: –0.36; –0.08, 
p = 0.002), while non-significant results were 
obtained for HDL-C and TG [230]. The results of 
a  small RCT suggest that CLA supplementation 
could impair endothelial function [231].
Safety: In 2008, FDA categorized CLA as gener-
ally recognized as safe. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
III C 1–6 g –5% Not 
demon-
strated
↓ FMD 
(Wors-
ened)
5.11. Other nutraceuticals
Other nutraceuticals commonly cited as im-
proving cholesterol metabolism are resveratrol 
and Hibiscus sabdarrifa L. (sour tea), but their 
lipid-lowering effects are not substantiated by 
available data [232, 233]. However, sour tea could 
have a  significant blood pressure decreasing ef-
fect [234]. Astaxanthin, a powerful antioxidant ca-
rotenoid, is often cited as having a lipid-lowering 
effect, but this effect is not supported by clinical 
evidence, while its supplementation is associated 
with a mild but significant improvement in fasting 
plasma glucose [235].
6. Nutraceutical combinations
Rational combinations of nutraceuticals with 
different lipid-lowering activities, particularly 
when associated with an appropriate lifestyle, 
should provide an alternative to drug treatment 
in patients in primary CVD prevention with mildly 
elevated LDL-C (especially for those who are not 
on target) and in some statin-intolerant patients 
[236]. There are many nutraceuticals with signif-
icant lipid-lowering properties. Most of them are 
used in combination with a  low dosage of other 
nutraceuticals, statins and other lipid-lowering 
drugs, because that allows the risk of side effects 
to be reduced and the efficacy to be improved 
(reducing the residual CV risk) [237]. Moreover, 
natural products with different mechanisms of ac-
tion can be associated to achieve a potential syn-
ergetic effect, acting on the absorption of lipids 
from the bowel and/or increasing their excretion 
(soluble fibers, glucomannan, plant sterols, probi-
otics), enhancing the hepatic uptake of cholesterol 
(berberine, soybean proteins), inducing LDL-C ex-
cretion (berberine, soy proteins, chlorogenic acid), 
inhibiting HMG-CoA reductase enzyme and limit-
ing the hepatic synthesis of cholesterol (monaco-
lins, policosanols, allicin, soybean proteins, berga-
mot), reducing the oxidation of LDL and increasing 
thermogenesis and lipid metabolism (chlorogenic 
acid) [238]. 
For the below combination therapies no mech-
anism of action is described, as it has been pre-
sented in detail in the previous sections. 
6.1. Red yeast rice and policosanols
Efficacy: The association of red yeast rice extract 
(340 mg containing 5 mg of MonK) and octacosa-
nols (10 mg) was tested in 111 patients with mod-
erate hypercholesterolemia, normal/border-line 
triglyceridemia and low CVD risk (< 20% accord-
ing to the Framingham Risk Score (FRS)). The re-
duction of LDL-C was 20% and it was similar to 
that obtained with pravastatin at the dose 20 mg/ 
day, without any serious safety concerns [239]. 
The efficacy of the combination of red yeast rice 
extract (200 mg, corresponding to 3 mg of MonK) 
with linear aliphatic alcohols (10 mg) was also 
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evaluated in the treatment of primary-moderate 
hypercholesterolemia with a  placebo-controlled 
clinical trial on 240 patients with overall coronary 
risk < 20% (FRS); after 4 months a significant re-
duction in LDL-C (–29%) and non-HDL-C (–26%) 
(p < 0.001) was achieved [240]. The combination 
of red yeast rice extract (200 mg, corresponding to 
3 mg of Monacolin K) with policosanol (10 mg) was 
also tested in a  large single-blind, randomized, 
multicenter study in 411 centers, comparing the 
effect of the nutraceutical association plus diet 
versus diet alone with a follow-up of 16 weeks. In 
2408 eligible subjects (1665 adults and 743 elder-
ly), LDL-C was reduced by 21%, while HDL-C im-
proved by 13%, without significant changes in TG 
levels [241]. Beneficial results were also obtained 
in 40 children with heterozygous familial hyper-
cholesterolemia (HeFH) and familial combined 
hyperlipidemia (FCH), who received a dietary sup-
plement containing red yeast rice extract (200 mg, 
corresponding to 3 mg of monacolins) and polico-
sanols (10 mg) for 8 weeks; the treatment was ef-
fective, safe and well tolerated [242].
Safety: Based on the data from all above-men-
tioned studies, no serious safety concerns have 
been raised. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
I A Mona-
colin K 
3–5 mg, 
policosa-
nol  
10 mg
–15% to 
–21% 
Not 
demon-
strated 
Not 
demon-
strated 
6.2.  Red yeast rice, policosanols  
and berberine
Efficacy: The association of the lipid-lowering 
properties of red yeast rice (3 mg MonK), poli-
cosanols (10 mg) and berberine (500 mg) is the 
most studied in RCTs and the only one for which 
meta-analyses of RCTs are available. A recent me-
ta-analysis of 14 RCTs including data from 3159 
subjects showed than the red yeast rice-polico-
sanol-berberine association improved the plas-
ma level of LDL-C by –0.61 mmol/l (23.6 mg/dl) 
(p < 0.001), HDL-C by 0.07 mmol/l (2.71 mg/dl) 
(p < 0.001), TG by –0.16 mmol/l (14.2 mg/dl) (p < 
0.001) and glucose by –0.14 mmol/l (2.52 mg/dl) 
(p = 0.010). Moreover, the improvement in both 
lipid and glucose profile appeared to be main-
tained in the long-term observation [243]. Then, 
the improvement of lipid profile was not depen-
dent on duration of supplementation or baseline 
lipid levels, while a  greater glucose-lowering ef-
fect was found with higher baseline glucose levels 
and longer durations of supplementation [244]. 
Moreover, the efficacy of this nutraceutical com-
bination was investigated in a recent clinical trial 
that involved 100 subjects with low-grade sys-
temic inflammation (hs-CRP levels > 2 mg/l) and 
normal-borderline cholesterol levels (LDL-C = 100–
160 mg/dl (2.5–4.1 mmol/l)). After 3 months of 
treatment a reduction of LDL-C (−23%) (p < 0.001) 
was reported; hs-CRP and endothelial micro-
particle levels were also significantly decreased 
(–41% and –16%, respectively). It was highlighted 
that LDL-C change was positively associated with 
hs-CRP (p = 0.04) and endothelial microparticle 
changes (p < 0.001); hs-CRP and endothelial mi-
croparticle changes were also related to each oth-
er (p = 0.005). Therefore, in addition to improving 
cholesterol profile, there is potential for this com-
bination of nutraceuticals to attenuate the degree 
of systemic inflammation and endothelial injury 
in subjects with low-grade systemic inflammation 
[244]. This combination has also been tested in 
adult and elderly patients previously intolerant 
to statins [245, 246], being well tolerated in 80% 
of cases. The genetic variants of LDLR and PCSK9 
that could be related to variations in response to 
lipid-lowering effects of this supplement have also 
been investigated. Three polymorphisms in the 
3′ UTR region of LDLR and two in the 5′ UTR region 
of PCSK9 were associated with response to the 
treatment. These results could explain the vari-
ability observed in the response among patients 
with moderate hypercholesterolemia, and they 
may be useful in identifying subjects who could 
potentially benefit the most from this supplemen-
tation [247]. It was also observed that endothelial 
function and PWV were improved by the combina-
tion of red yeast rice and berberine in dyslipidae-
mic patients [248, 249].
Safety: Based on the available data, no serious 
safety concerns have been raised. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
I A Monacol-
in K  
3 mg, 
polico-
sanol 
10 mg, 
berber-
ine  
500 mg
–20% to 
–25% 
↓ hs-
CRP, TG, 
glucose
↑ FMD,  
↓ PWV
6.3. Red yeast rice and plant sterols
Efficacy: The association of plant sterols/sta-
nols with certain lipid-lowering ingredients was 
demonstrated to strengthen cholesterol-lower-
ing efficacy and add TG-lowering effects [250]. 
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A  small cohort of hypercholesterolemic patients 
(18 subjects) was assigned to the intake of a nu-
traceutical product containing red yeast rice 1200 
mg (titration in monacolin K not reported) and 
phytosterols 1250 mg per daily dose. The results 
showed a reduction of LDL-C of 33% (1.37 mmol/l 
(53 mg/dl)) after 6 weeks of treatment (p < 0.05) 
[251]. These results have been recently confirmed 
in a  double-blind, placebo-controlled, random-
ized clinical trial evaluating the effect of phytos-
terols 800 mg, red yeast rice (monacolin K 5 mg) 
and their association in 90 hypercholesterolemic 
subjects. The group treated with the nutraceuti-
cal association experienced a LDL-C reduction by 
–27.0% and apoB decrease by –19.0% (both, p < 
0.001) [252].
Safety: In the available studies none of the 
participants reported any muscle pains and no 
abnormal liver function tests were observed while 
taking this supplement. However, further studies 
with longer follow-up are necessary to conclusive-
ly confirm this. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIa B Mona-
colin K  
5–10 mg, 
phytos-
terols 
800–
1250 mg
–25% to 
–30% 
↓ ApoB Not 
demon-
strated 
6.4. Red yeast rice and artichoke
Efficacy: Red yeast rice and artichoke have 
been combined with other nutraceuticals in or-
der to test their activity on lipid parameters and 
inflammation. Some available trials have been 
carried out on an association of red yeast rice 
(166.67 mg, 0.4% monacolin K), sugar cane-de-
rived policosanols (3.70 mg, 90% policosanols–
octacosanol 60%), and artichoke leaf extracts 
(200 mg, 5–6% chlorogenic acid) to be taken 
as 3 tablets per day. In a  double-blind, random-
ized, parallel controlled study on 39 subjects 
with moderate hypercholesterolemia, after 16 
weeks of treatment, LDL-C was reduced by 21.4% 
(95% CI: –13.3; –24.9%, p < 0.001), while TG de-
creased by 12.2% (95% CI: –24.4; –0.1%, p < 0.05) 
[253]. In a 16-week, randomized, double-blind, pla-
cebo-controlled trial carried out on 100 subjects the 
authors observed a reduction of LDL-C by 14.3% 
(–0.57 mmol/l (22 mg/dl), 95% CI: –0.8; –0.31), 
as well as TC, apoB100 and apoB100/apoA-I ratio, 
without modifying safety parameters [254]. Dou-
bling the daily dose seemed not to add additional 
benefits, while there were no safety concerns also 
with the higher dosage [255]. The association of 
red yeast rice (200 mg, containing monacolin K 
10 mg), artichoke extract (500 mg), and banaba 
extract (50 mg) was evaluated in a double-bind, 
placebo-controlled, cross-over designed trial in 
30 adults with suboptimal LDL-C levels, in prima-
ry prevention of CVD. Patients followed a period 
of 6 weeks of treatment with a  nutraceutical or 
placebo, then 2 weeks of washout and finally 
6 weeks in crossover. After the active treatment, 
there was observed a significant improvement in 
LDL-C (–18.2%), non-HDL-C (–15%), glutamic ox-
aloacetic transaminase (–10%), glutamate-pyru-
vate transaminase (–30.9%), and hs-CRP (–18.2%) 
vs. placebo. No changes were observed in the oth-
er investigated parameters in both groups [256].
Safety: Based on the available data, no seri-
ous safety concerns have been raised, but further 
studies with longer follow-up are necessary to 
conclusively confirm this.
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIa B Mona-
colin K  
2–10 mg, 
arti-
choke 
extract 
500– 
600 mg
–14% to 
–21% 
↓ hs-CRP, 
TG
Not 
demon-
strated 
6.5.  Red yeast rice, policosanol, and silymarin 
Efficacy: A double-blind, placebo-controlled tri-
al evaluated the effects of a combination of red 
yeast rice (334 mg containing monacolin 10 mg), 
policosanol (30 mg), and silymarin (150 mg) com-
pared to placebo on lipid profile, endothelial and 
inflammatory parameters in 134 low-risk dys-
lipidemic patients. After 3 months of treatment, 
the nutraceutical supplement decreased LDL-C 
compared to baseline (p = 0.041) and to place-
bo (p = 0.037, respectively). Triglycerides were 
reduced by the active product (p = 0.039), but 
not by the placebo, even though, in the group-
to-group comparison, no significant difference 
was recorded (p = 0.061). All tested inflamma-
tory parameters (soluble intercellular adhesion 
molecule-1, soluble vascular cell adhesion mole-
cule-1, soluble E-selectin, MMP-2 and -9, hs-CRP, 
IL-6 and TNF-α) were reduced by the nutraceu-
tical combination [257]. Another research group 
tested the same combination in a  group of 80 
hypercholesterolemic subjects in an 8-week ran-
domized clinical trial. When compared to place-
bo, nutraceutical combination treated patients 
experienced a more favorable percentage change 
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in LDL-C (–23.3%), hs-CRP (–2.4%), and endo-
thelial function (pulse volume displacement vs. 
baseline: +17%). No significant difference was 
observed with respect to effects on TG, HDL-C 
and safety parameters [258]. 
Safety: Further studies with a  long follow-up 
are necessary to evaluate the safety issues for this 
combination. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIb B Mona-
colin K 
10 mg, 
policosa-
nol  
30 mg, 
silymarin 
150 mg
–14% to 
–23% 
↓ 
inflam-
matory 
biomark-
ers
↑ FMD
6.6. Red yeast rice and antioxidants
Efficacy: A nutraceutical supplement composed 
of red yeast rice (10 mg MonK) and coenzyme Q10 
(CoQ10) (30 mg) was tested in a  double-blind, 
placebo-controlled, crossover, randomized clini-
cal trial carried out on 25 healthy, mildly hyper-
cholesterolemic subjects. The treatment duration 
was 4 weeks. When compared to the placebo 
group, monacolins/CoQ10-treated patients ex-
perienced a  more favorable percent change in 
LDL-C (–21.99%, 95% CI: –26.63; –17.36), non-
HDL-C (–14.67%, 95% CI: –19.22; –10.11), MMP-2 
(–28.05%, 95% CI: –35.18; –20.93), MMP-9 
(–27.19%, 95% CI: –36.21; –18.15), and hs-CRP 
(–23.77%, 95% CI: –30.54; –17.01). No signifi-
cant differences were observed with respect to 
TGs, HDL-C, and safety parameters [259]. The 
same combination was then evaluated in 40 
moderately hypercholesterolemic subjects with 
a  double-blind, placebo-controlled, randomized 
clinical trial. After 6 months of active treat-
ment, the results showed a  more favourable 
percentage change in LDL-C (–26.3%; p < 0.05), 
endothelial reactivity (PV displacement: +6.0%; 
p < 0.05) and arterial stiffness (PWV: –4.7%; p < 
0.05) [260]. Red yeast rice (10 mg monacolins) 
has also been associated with a pool of antiox-
idants (green tea dry extract, 100 mg; CoQ10, 
20 mg; astaxanthin, 2 mg; resveratrol, 20 mg; 
and quercetin, 50 mg) and has been tested in 
a  crossover, double-blind, placebo-controlled 
randomized clinical trial on 25 moderately hy-
percholesterolemic, pharmacologically untreat-
ed subjects, as primary prevention for CVD. After 
4 weeks of the active treatment patients expe-
rienced an improvement of cholesterol levels 
(LDL-C –22.36%; non-HDL-C –22.83%), hs-CRP 
–2.33% and endothelial function (PV displace-
ment after monacolin treatment, 18.59%) [261]. 
Safety: Based on the available data, no serious 
safety concerns have been raised.
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIa B Mona-
colin K 
10 mg, 
CoQ10 
or other 
antioxi-
dants
–20% to 
–26% 
↓ hs-CRP ↑ FMD,  
↓ PWV
6.7.  Berberine combined with bioactive 
lipid-lowering agents other than red 
yeast rice
Efficacy: Berberis aristata extract (588 mg, con-
taining 500 mg berberine) was combined with 
chlorogenic acid (67 mg) and tocotrienols (143 mg) 
in a double-blind, cross-over designed trial versus 
placebo, in 40 overweight subjects with mixed 
hyperlipidemia. After 8 weeks of treatment, there 
was observed a significant improvement in LDL-C 
(–24%), TG (–19%), non-HDL-C (–22%), fasting 
insulin (–5%) and HOMA index (–10%) [262]. An-
other double-blind, placebo-controlled, crossover 
RCT tested the efficacy of the administration 
of Berberis aristata (588 mg extract containing 
500 mg berberine) with Silybum marianum (105 mg 
extract) twice a day in 102 dyslipidemic patients. 
The results showed a reduction of LDL-C and TG, 
and an increase of HDL-C after the first 3 months 
of treatment; the lipid profile worsened after 
a  2-month washout period and improved again 
when the nutraceutical combination was reintro-
duced for a further 3 months [263]. Given the low 
lipid-lowering activity of components different 
from berberine, it is not clear whether the observed 
effects are related to berberine per se or not. 
Safety: Based on the available data, no seri-
ous safety concerns have been raised, but further 
studies with a long follow-up are still necessary to 
confirm this. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIb B Ber-
berine 
500–
1000 mg, 
CoQ10 
or other 
antioxi-
dants
–16% to 
–24% 
↓ TG, 
HOMA 
index
Not 
demon-
strated 
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6.8. Soy proteins and plant sterols
Efficacy: Low dosed soy proteins and plant 
sterols have been demonstrated to have mild 
but additive cholesterol-lowering effects in hu-
mans [264]. The intake of soy proteins with 
plant sterols in patients with MetS and LDL-C ≥ 
160 mg/dl (4.1 mmol/l) showed a  significant 
(p < 0.05) improvement in LDL-C, non-HDL-C, cho-
lesterol/HDL-C and TG/HDL-C ratios, apoB, apoB/ 
apoA-1 ratio, homocysteine, total LDL particle 
number and large HDL particle number, in partic-
ular after 12 weeks of treatment [265]. Soy pro-
teins (16.2 g/1000 kcal) and plant sterols (1.2 g/ 
1000 kcal) were also combined with viscous fibers 
(8.3 g/1000 kcal) and almonds (16.6 g/1000 kcal) 
in the treatment of a small cohort of hypercholes-
terolemic subjects: after their intake for 4 weeks, 
there was reported a  reduction of LDL-C of 35.0 
±3.1% (p < 0.001), and the ratio of LDL-C to HDL-C 
(30.0 ±3.5%, p < 0.001) [266].
Safety: Based on the available data, no safety 
concerns have been raised, but further studies 
with a  long follow-up are still necessary to con-
firm this. 
Class Level Active 
daily 
doses
Expected 
effects 
on LDL-C
Effects 
on other 
CV risk 
biomark-
ers
Direct 
vascular 
effects
IIa B Soy 
protein 
8–25 g, 
phytos-
terols 
800–
2000 mg
–16% to 
–30% 
↓ ApoB Not 
demon-
strated 
6.9.  Different nutraceutical combinations 
supported by single RCTs
For these combined products, due to lack of 
enough data, is not possible, at this moment, to 
suggest a final classification. The level of evidence 
might have been limited to “B” or “C” – expert 
opinion with the class of suggestion “IIb” waiting 
for confirmative trials.
6.9.1.  Red yeast rice and omega-3 
polyunsaturated fatty acids
Efficacy: The efficacy of a combined nutraceu-
tical with red yeast rice (5 mg monacolin K) and 
PUFAs (610 mg: 183 mg EPA, 122 mg DHA) was 
evaluated in a clinical trial on 107 pharmacologi-
cally untreated subjects, affected by primary poly-
genic hypercholesterolemia and MetS, in primary 
prevention for CVD. After 8 weeks of treatment, 
the results showed a significant decrease in LDL-C 
(–0.97 ±0.35 mmol/l (37.5 mg/dl); –22 ±3%), TG 
(–0.22 ±0.28 mmol/l (19.5 mg/dl); –9 ±5%) and 
non-HDL-C (–21 ±3%) and a significant increase in 
HDL-C (+1.5 ±0.5%) (p < 0.001 for all), without the 
modification of safety parameters. In particular, 
75% of subjects reached an LDL-C target of less 
than 160 mg/dl and 25% of less than 130 mg/dl. 
Moreover, the study highlighted a  greater de-
crease in TG levels only in patients with baseline 
TG > 500 mg/dl, who showed a  11% reduction 
(p < 0.001 vs. subjects with baseline TG < 150 mg/dl) 
[267].
Safety: No safety concerns. Very limited data; 
further studies are necessary. 
6.9.2.  Red yeast rice, bitter gourd chlorella, 
soy protein, and licorice
Efficacy: Extracts from red yeast rice, bitter 
gourd, chlorella, soy protein and licorice were 
combined to evaluate their effects in subjects 
with MetS in a  12-week, randomized, placebo- 
controlled clinical trial (106 participants). Each tab-
let was composed 0.37 g of red yeast rice, 40 g of 
fresh bitter gourd, 1.5 g of chlorella, 1.1 g of soy-
bean and 2.2 g of licorice. The active group was 
treated with three tablets/day. LDL-C decreased 
significantly after the treatment (3.4 ±0.7 (131 mg/ 
dl) to 2.7 ±0.5 mmol/l (104 mg/dl), p < 0.001). 
In addition, TGs were reduced (–0.2 ±0.3 mmol/l 
(18 mg/dl), p = 0.039). Moreover, this nutraceuti-
cal compound has also shown potential in normal-
izing blood pressure [268]. 
Safety: No safety concerns. Very limited data; 
further studies are necessary. 
6.9.3. Psyllium and plant sterols
Efficacy: A nutraceutical supplement with psyl-
lium (7.68 g) and plant sterols (2.6 g) was admin-
istered to a small cohort of subjects (33 patients), 
with LDL-C levels between 2.58 (100 mg/dl) and 
4.13 mmol/l (160 mg/dl), in a placebo-controlled 
clinical trial. Subjects were treated for 4 weeks 
with the nutraceutical combination vs. placebo, 
followed by a 3-week washout period, and finally 
received the alternative treatment (placebo/nutra-
ceutical) for another 4 weeks. The improvement 
in lipid profile included a reduction of LDL-C from 
3.5 ±0.7 mmol/l (135 mg/dl) to 3.1 ±0.8 mmol/l 
(120 mg/dl) after the intake of the nutraceutical 
product (p < 0.01). Moreover, this combination 
led to a reduction of plasma apoB concentrations 
(p < 0.01) [269].
Safety: No safety concerns. Very limited data; 
further studies are necessary. 
6.9.4.  Psyllium and n-3 polyunsaturated 
fatty acids
Efficacy: Plant sterols with omega-3 fatty acids 
have synergistic lipid-lowering effects, as demon-
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strated in a  3-week randomized, placebo con-
trolled clinical trial on 60 hyperlipidemic individ-
uals. The participants were divided into 4 groups 
and received either Sunola oil or ω-3 long chain 
PUFAs capsules (1.4 g/day) with or without phy-
tosterols (2 g) or placebo. The combination of phy-
tosterols and ω-3 PUFAs reduced LDL-C by 12.5% 
(p = 0.002) and TG by 25.9% (p = 0.005); more-
over, it increased HDL-C (8.6%, p = 0.04) [270].
Safety: No safety concerns. Very limited data; 
further studies are necessary. 
6.9.5.  Garlic and omega-3 polyunsaturated 
fatty acids
Efficacy: Garlic oil (500 mg) and fish oil (600 mg) 
were administered to a small sample of hypercho-
lesterolemic subjects (16 patients) for 2 months 
and compared with a control group (16 patients). 
The results showed an improvement of lipid pa-
rameters: LDL-C –21%, TG –37%, VLDL –36.7%, 
TC/HDL-C ratio –23.4%, HDL-C +5.1% [271].
Safety: No safety concerns. Very limited data; 
further studies are necessary. 
6.9.6.  g-oryzanol and ω-3 polyunsaturated 
fatty acids
Efficacy: The combination of g-oryzanol (40 mg) 
with ω-3 polyunsaturated fatty acids (1100 mg) 
was demonstrated to improve lipid profile (LDL-C 
–0.93 ±0.97 mmol/l (36 mg/dl), p < 0.0001, TG 
–0.60 ±0.63 mmol/l (23.2 mg/dl), all p < 0.001), 
as well as inflammatory and oxidative status in 
dyslipidemic volunteers [272].
Safety: No safety concerns. Very limited data; 
further studies are necessary. 
6.9.7. Plant proteins and soluble fibers
Efficacy: Plant proteins (lupin protein or pea 
protein) associated with soluble fibers (oat fiber 
or apple pectin) demonstrated lipid-lowering ac-
tivity in hypercholesterolemic patients in prima-
ry prevention of CVD: significant reductions of 
TC levels were observed in all groups (each one 
with 25 subjects), in particular lupin protein + cel-
lulose (–0.3 mmol/l (11.6 mg/dl), –4.2%), casein 
+ apple pectin (–0.39 mmol/l (15 mg/dl), –5.3%), 
pea protein + oat fiber (–0.35 mmol/l (13.5 mg/dl), 
–4.7%) and pea protein + apple pectin (–0.43 
mmol/l (16.6 mg/dl), –6.4%) (p < 0.05). Moreover, 
LDL-C was significantly reduced in pea protein + ap-
ple pectin combinations (–0.27 mmol/l (10.4 mg/ 
dl), 9.2%) (p < 0.004 vs. control). The association 
of pea protein + oat fiber also showed 4% glucose 
reduction, 57% insulin reduction and 25% de-
crease of the HOMA index [273].
Safety: No safety concerns. Very limited data; 
further studies are necessary. 
6.9.8. Glucomannan and plant sterols 
Efficacy: Glucomannan (10 g/day) and plant 
sterols (1.8 g/day) were tested in a  randomized, 
crossover trial on 34 mild hypercholesterolemic 
subjects. The study consisted of four phases of 
21 days, with each phase separated by a 28-day 
washout. An improvement of lipid parameters 
was assessed after the treatment (LDL-C 2.9 ±0.2 
mmol/l (112 mg/dl) vs. control group 3.6 ±0.2 
mmol/l (140 mg/dl), p < 0.05). Plasma lathosterol 
concentrations, an index of cholesterol biosynthe-
sis, were lowered after the combination treatment 
(p < 0.05), as well [274]. 
Safety: No safety concerns. Very limited data; 
further studies are necessary. 
6.9.9.  Pantethine, soybean plant sterols, 
green tea extract, delta-tocotrienol 
and phytolens
Efficacy: A  clinical trial on 30 hyperlipidemic 
untreated patients showed a significant improve-
ment in serum lipids using a nutraceutical prod-
uct with a  combination of pantethine (900 mg), 
soybean plant sterols (800 mg), green tea extract 
(600 mg containing 50% epigallocatechin gallate), 
g/δ tocotrienols from annatto seed (75 mg) and 
Phytolens from lentil husks (5 mg). After 2 months 
of treatment, there was a significant reduction of 
LDL-C by 14% (p < 0.003), VLDL dropped by 20% 
(p < 0.01) and sdLDL particles fell by 25% (type III 
and IV) [275].
Safety: No safety concerns. Very limited data; 
further studies are necessary. 
7. Nutraceuticals combined with 
pharmacological therapy
Many available data, including the most recent 
studies with PCSK9 inhibitors, support the LDL-C 
concept that “lower is better” [276]. Even know-
ing that statins are the drugs of choice in patients 
with high LDL-C levels and moderate-to-high CV 
risk, the use of high-intensity statins increases 
the side effects and therefore reduces the thera-
py adherence and compliance [277, 278]. On the 
other side, even with the good statin therapy tol-
erability, the LDL-C targeted levels might not be 
achieved for 30–70% of patients (depending on 
the risk), even in the combination with ezetimibe 
for high and very high risk patients [279]. Many 
nutraceutical options are available either alone or 
in combination with statins to help to reach rec-
ommended goals in a safe and tolerable way for 
most patients [280]. Clinical trials have reported 
that many nutraceuticals have an additive effect 
to lipid-lowering drugs, allowing the statin doses 
to be reduced without diminishing the results in 
terms of TC and LDL-C reduction and significant-
Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
Arch Med Sci 5, August / 2017 993
ly limiting adverse effects [281]. However, most 
of the combinations presented below have been 
tested only in a single study, and the obtained re-
sults have not been confirmed yet, so no recom-
mendations can be made. 
7.1.  Statins and polyunsaturated fatty acids
Efficacy: The effect of PUFAs in statin-treated 
subjects is simply addictive in terms of dose-relat-
ed TG reduction [282, 283]. Data from a long-term 
randomized clinical trial support the concept that 
combining statins with ω-3 fatty acids seems to 
further decrease CHD risk by 19% in primary pre-
vention [284] and CHD mortality by 17% in sec-
ondary prevention [285]. Given the availability of 
data on CVD event risk reduction the supplemen-
tation of PUFAs in statin-treated patients can be 
recommended, especially in hypertriglyceridemic 
and post-CHD patients.
Safety: No safety concerns; limited data – fur-
ther studies are necessary. 
7.2. Statins and soluble fibers
Efficacy: The lipid-lowering effects of psyl-
lium (10 g/day) and lovastatin (20 mg/day), 
alone and in combination, were evaluated on 
36 volunteers. After 4 weeks of treatment, the 
mean LDL-C and TG levels in the group receiving 
20 mg of lovastatin plus 10 g of psyllium fell by 
30.9% and 26.2% from baseline compared with 
24.8% and 32.9% in the group receiving 20 mg 
of lovastatin and 3.6% and 10.9% in the group 
receiving 10 g of psyllium, respectively [286]. An-
other 12-week blinded placebo-controlled study 
tested the effects of 20 mg of simvastatin plus 
placebo, 10 mg of simvastatin plus placebo or 
10 mg of simvastatin plus 15 g of psyllium daily, 
enrolling 68 patients. After 8 weeks, the mean 
lowering of LDL-C (–63 mg/dl/–1.63 mmol/l; 
p = 0.03) in the group receiving 20 mg of simvas-
tatin plus placebo was the same as that in the 
group receiving 10 mg of simvastatin plus psyl-
lium and was greater than that obtained with 
10 mg of simvastatin plus placebo (55 mg/dl/ 
1.42 mmol/l; p = 0.03). Similar results were re-
ported for apoB and TC, while there were not ob-
served significant changes of TG or HDL-C levels 
[287]. In a  further randomized, parallel-design 
clinical trial, patients with primary hypercho-
lesterolemia (n = 116) were assigned to receive 
a  daily dose of 25 g of fiber (corresponding to 
6 g of soluble fibers) plus rosuvastatin 40 mg 
(n = 28), rosuvastatin 40 mg alone (n = 30), sim-
vastatin 40 mg plus ezetimibe 10 mg plus 25 g 
of fiber (n = 28), or simvastatin 40 mg plus eze-
timibe 10 mg (n = 30) alone during 12 weeks. 
These therapies led to similar reductions in LDL-C 
and TC (p < 0.001 vs. baseline), while no change 
was observed in HDL-C. Among patients treated 
with highly effective lipid-lowering therapy, the 
intake of 25 g of fibers added favorable effects: 
a reduction of phytosterolemia, improvement in 
blood glucose (p = 0.047), weight loss (p = 0.04) 
and reduced body mass index (p = 0.002) [288]. 
Given the availability of data from different RCTs, 
the supplementation of fibers in statin-treated 
patients might be recommended especially in 
patients with stipsis or irritable bowel disease. 
It remains to be clarified however whether the 
supplemented fibers interfere with other drugs 
administered by patients at high CVD risk.
Safety: No safety concerns; limited data – fur-
ther studies are necessary. 
7.3.  Ezetimibe, red yeast rice, policosanol 
and berberine 
Efficacy: Ezetimibe and nutraceuticals have 
been both introduced, alone or in association, 
as alternative therapies for statin-intolerant pa-
tients and proved to be effective and well tolerat-
ed. A clinical trial evaluated the effects of a com-
bination of nutraceuticals (red yeast rice extract 
200 mg (equivalent to 3 mg monacolins), poli-
cosanol 10 mg, and berberine 500 mg) and eze-
timibe on statin-intolerant dyslipidemic subjects 
with IHD treated with PCI. At 1-year follow-up, 
58 (72.5%) patients of the combined thera-
py group (n = 86) reached the therapeutic goal 
(LDL-C < 2.58 mmol/l (100 mg/dl)). No patient 
experienced important undesirable effects [289]. 
Berberine (500 mg), red yeast rice (200 mg) and 
policosanol (10 mg) were also associated with 
ezetimibe (10 mg) in a study on 26 patients with 
primary hypercholesterolemia, with a  history of 
statin intolerance or refusing statin treatment. 
After 3 months of treatment, it was observed 
that this treatment was as effective as statins in 
moderate doses (LDL-C –37%, TG –23%) [290]. 
Safety: No safety concerns; limited data – fur-
ther studies are necessary.
7.4.  Ezetimibe or statins and berberine with 
silymarin 
Efficacy: Berberis aristata (588 mg, containing 
berberine 500 mg) and Silybum marianum (105 mg) 
extracts, twice a day, were administered to 45 pa-
tients diagnosed with type 2 diabetes with hyper-
cholesterolemia and statin intolerance. The intake 
of berberine/silymarin with statins led to an im-
provement of lipid parameters (LDL-C –15% and 
–28%, respectively after 6 and 12 months) and 
also when added to ezetimibe (LDL-C –20% and 
–33% respectively after 6 and 12 months). In the 
control group, in which only berberine/silymarin 
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was administered, there was also a  reduction 
of LDL-C (LDL-C –17% and –26% respectively af-
ter 6 and 12 months). Glycemic control improved 
in all groups. All reported side effects lasted 
a  few days and did not lead to interruption of 
treatment [291]. 
Safety: No safety concerns; limited data – fur-
ther studies are necessary. 
7.5. Statins/ezetimibe and plant sterols
Efficacy: A randomized clinical trial with paral-
lel arms was designed to evaluate the lipid-low-
ering effects of the addition of plant sterols to 
lipid-lowering drugs. Eighty-six subjects were 
submitted to a 4-week run-in period with ator-
vastatin 10 mg (baseline), followed by another 
4-week period in which subjects received ator-
vastatin 40 mg, ezetimibe 10 mg or a  combi-
nation of both drugs (phase I); finally, capsules 
containing 2.0 g of plant sterols were added to 
previous assigned treatments for 4 weeks (phase 
II). Compared with baseline, atorvastatin 40 mg 
showed a reduction of LDL-C (22%, p < 0.05), and 
increased β-sitosterol, campesterol/cholesterol, 
and β-sitosterol/cholesterol ratios (39%, 47%, 
and 32%, respectively, p < 0.05); ezetimibe 10 mg 
reduced campesterol and campesterol/cholester-
ol ratio (67% and 70%, respectively, p < 0.05), 
while the combined therapy decreased LDL-C 
(38%, p < 0.05), campesterol, β-sitosterol, and 
campesterol/cholesterol ratio (54%, 40%, and 
27%, p < 0.05). This study demonstrated that the 
addition of plant sterols further reduced LDL-C 
by ∼6.5% in the atorvastatin therapy group and 
5.0% and 4.0% in the combined therapy group 
(p < 0.05 for all) [292].
Eleven hypercholesterolemic coronary pa-
tients on a low-fat, low-cholesterol baseline diet 
added simvastatin (20 mg/day) for 3 months 
and then dietary plant stanol ester margarine 
(2.25 g of stanols/day) for 8 weeks; afterwards, 
cholestyramine 8 g/day was added for another 
8 weeks. The results highlighted that simvasta-
tin reduced LDL-C by 39% (p < 0.001) and addi-
tional stanol ester margarine reduced it by a fur-
ther 13% (p < 0.05). The triple treatment led to 
67% reduction from baseline (p < 0.001), with all 
LDL-C values being < 2.6 mmol/l, and increased 
HDL-C by 15% (p < 0.01). It also increased the 
serum lathosterol/cholesterol ratio (p < 0.01), 
thus showing upregulation of cholesterol syn-
thesis, and increased the serum sitosterol ratio 
(p < 0.01). These results support the use of sta-
nol ester with only moderate doses of statin and 
resin to control LDL-C levels in hypercholesterol-
emic patients [293].
Safety: No safety concerns; limited data – fur-
ther studies are necessary. 
7.6. Statins and tocotrienols
Efficacy: A clinical trial with 28 hypercholester-
olemic subjects was carried out to assess the ef-
ficacy of the tocotrienol-rich fraction of rice bran 
alone and in the combination with lovastatin. 
The combination of the tocotrienol-rich fraction 
(50 mg) and lovastatin (10 mg) plus the AHA step-
1 diet was demonstrated to significantly reduce 
LDL-C by 25% (p < 0.001), an additional 10% in 
comparison to statin therapy alone [294].
Safety: No safety concerns; limited data – fur-
ther studies are necessary. 
7.7. Statins and bergamot 
Efficacy: The association of bergamot-derived 
polyphenolic fraction (1000 mg/daily for 30 days) 
with rosuvastatin (10 mg/day for 30 days) was 
evaluated in a  study that enrolled 77 patients 
with mixed hyperlipidemia. It was observed that 
the combined therapy significantly reduced LDL-C 
(–53%) compared to rosuvastatin alone, an effect 
which was nearly the same as the one produced 
by 20 mg of rosuvastatin. In addition, TGs were 
reduced by 36% and HDL-C increased by 37%, an 
effect that was significantly higher when com-
pared to the use of rosuvastatin alone. Moreover, 
a significant reduction of biomarkers used for de-
tecting oxidative vascular damage was reported, 
suggesting antioxidant activity of bergamot in pa-
tients on statin therapy [120].
Safety: No safety concerns; limited data – fur-
ther studies are necessary. 
7.8. Statins and garlic
Efficacy: The therapeutic effect of the combi-
nation of black seed with garlic as a  treatment 
for dyslipidemia was evaluated in a  randomized, 
double-blind, placebo-controlled, two arms parallel 
study on 258 subjects who met the Adult Treatment 
Panel (ATP)-III criteria for drug treatment of hyper-
lipidemia and dietary intervention. Patients who fol-
lowed 8-week treatment with simvastatin (10 mg) 
plus placebo obtained a significant reduction in non-
HDL-C (–10.8%), TG (–6.9%), and LDL-C (–11.6%) 
(p ≤ 0.01), and an increase in HDL-C (+10.4%) (p = 
0.02). Patients who received simvastatin (10 mg), 
plus black seed (500 mg) and garlic (250 mg) for 
8 weeks showed a greater improvement of lipid pa-
rameters, LDL-C (–29.4%), TG (–20.1%), non-HDL-C 
(–27.4%), and HDL-C (+21.4%) (p = 0.01). The high-
er (2.1 to 2.9 times) results obtained with simvas-
tatin plus black seed and garlic as compared to the 
other group demonstrated the synergetic effect of 
this association of a nutraceutical combination with 
pharmacological treatment [295].
Safety: No safety concerns; limited data – fur-
ther studies are necessary. 
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7.9. Statins and vitamin D
Efficacy: Low vitamin D status has been as-
sociated with hyperlipidemia. A  double-blind, 
placebo-controlled trial was assessed on 56 hy-
percholesterolemic patients, who were randomly 
assigned to receive vitamin D 200 IU/day (n = 
28) or a placebo (n = 28) as an add-on to statin 
for 6 months. At the end of the treatment, sub-
jects who received vitamin D supplementation 
had an increased level of serum 25-hydroxyvita- 
min D concentrations compared with placebo 
(+16.3 ±11.4 compared with +2.4 ±7.1 ng/ml; 
p < 0.001). Moreover, the differences in TC and 
TG levels between the statin + vitamin D group 
and statin + placebo group were significant: 
–0.57 mmol/l (22 mg/dl) (95% CI: –0.83; –0.32, 
p < 0.001) and –0.32 mmol/l (28.3 mg/dl) (95% CI: 
–0.55; –0.09, p < 0.001), respectively. Moreover, in 
patients with 25-hydroxyvitamin D level < 30 ng/ 
ml at baseline (n = 43), serum TC and TG lev-
els were further reduced by –0.74 ±0.31 mmol/l 
(28 mg/dl) (p < 0.001) and –0.42 ±0.22 mmol/l 
(37 mg/dl) (p < 0.001), respectively. Therefore, 
the intake of vitamin D together with statin can 
be a useful tool in the management of hypercho-
lesterolemic subjects [296]. Taking into consid-
eration that low serum vitamin D level seems to 
be associated with CVD risk and development of 
statin-related myopathy, the supplementation of 
vitamin D should always be considered in subjects 
with low vitamin D levels [297].
Safety: No safety concerns; limited data – fur-
ther studies are necessary. 
8. Conclusions
A  large number of nutraceuticals have been 
tested in available trials, demonstrating their lip-
id-lowering effects. It is, however, important to 
once again emphasize that nutraceuticals can-
not replace lipid-lowering therapy but might es-
sentially help to optimize it (reducing CV residual 
risk). Taking into account the influence of some 
of the presented nutraceuticals on different lip-
id parameters, it seems that this therapy might 
be especially important to consider for patients 
with mixed dyslipidemia, especially atherogenic 
dyslipidemia in patients with diabetes and MetS, 
in patients with low-to-moderate hypercholes-
terolemia not on target, as well as in all patients 
with statin-associated side effects, who cannot be 
treated with statins/suitable doses of statins and 
are at higher risk of CV events [298]. 
However, the main concern is still which lip-
id-lowering effects of nutraceuticals are clinically 
relevant, which are maintained in the long term 
and which might also be associated with an im-
provement in CVD risk. Combinations of lipid-low-
ering nutraceuticals could improve their safety (re-
ducing the dosages of the single components), but 
their efficacy has been rarely tested in more than 
one study/RCT, while some of the tested nutraceu-
tical combinations contained underdosed compo-
nents. On the other hand, both single components 
and some combinations (in particular red yeast rice, 
berberine, policosanol combination) have proved to 
maintain their efficacy in the long term (years), to 
have a  positive impact on CVD risk factors other 
than LDL-C, and to improve some markers of vas-
cular aging (endothelial function, pulse wave veloc-
ity). Finally, some nutraceuticals have been shown 
to significantly improve the efficacy of standard 
pharmacological treatments. In this context, an 
evidence-based approach to the use of lipid-low-
ering nutraceuticals could improve the quality of 
the treatment, including therapy adherence, and 
achievement of the LDL-C goal in clinical practice. 
However, it has to be clearly stressed that there are 
still no outcome studies proving that nutraceuticals 
can prevent CVD morbidity or mortality.
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